The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot.
Endogenous substances, usually proteins, that are involved in the blood coagulation process.
Laboratory tests for evaluating the individual's clotting mechanism.
A disorder characterized by procoagulant substances entering the general circulation causing a systemic thrombotic process. The activation of the clotting mechanism may arise from any of a number of disorders. A majority of the patients manifest skin lesions, sometimes leading to PURPURA FULMINANS.
Hemorrhagic and thrombotic disorders that occur as a consequence of abnormalities in blood coagulation due to a variety of factors such as COAGULATION PROTEIN DISORDERS; BLOOD PLATELET DISORDERS; BLOOD PROTEIN DISORDERS or nutritional conditions.
Constituent composed of protein and phospholipid that is widely distributed in many tissues. It serves as a cofactor with factor VIIa to activate factor X in the extrinsic pathway of blood coagulation.
Activated form of factor X that participates in both the intrinsic and extrinsic pathways of blood coagulation. It catalyzes the conversion of prothrombin to thrombin in conjunction with other cofactors.
Clotting time of PLASMA recalcified in the presence of excess TISSUE THROMBOPLASTIN. Factors measured are FIBRINOGEN; PROTHROMBIN; FACTOR V; FACTOR VII; and FACTOR X. It is used for monitoring anticoagulant therapy with COUMARINS.
Heat- and storage-stable plasma protein that is activated by tissue thromboplastin to form factor VIIa in the extrinsic pathway of blood coagulation. The activated form then catalyzes the activation of factor X to factor Xa.
The time required for the appearance of FIBRIN strands following the mixing of PLASMA with phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides). It is a test of the intrinsic pathway (factors VIII, IX, XI, and XII) and the common pathway (fibrinogen, prothrombin, factors V and X) of BLOOD COAGULATION. It is used as a screening test and to monitor HEPARIN therapy.
Storage-stable glycoprotein blood coagulation factor that can be activated to factor Xa by both the intrinsic and extrinsic pathways. A deficiency of factor X, sometimes called Stuart-Prower factor deficiency, may lead to a systemic coagulation disorder.
A plasma protein that is the inactive precursor of thrombin. It is converted to thrombin by a prothrombin activator complex consisting of factor Xa, factor V, phospholipid, and calcium ions. Deficiency of prothrombin leads to hypoprothrombinemia.
Storage-stable blood coagulation factor acting in the intrinsic pathway. Its activated form, IXa, forms a complex with factor VIII and calcium on platelet factor 3 to activate factor X to Xa. Deficiency of factor IX results in HEMOPHILIA B (Christmas Disease).
Use of a thrombelastograph, which provides a continuous graphic record of the physical shape of a clot during fibrin formation and subsequent lysis.
Activated form of factor VII. Factor VIIa activates factor X in the extrinsic pathway of blood coagulation.
An enzyme formed from PROTHROMBIN that converts FIBRINOGEN to FIBRIN.
A fibrin-stabilizing plasma enzyme (TRANSGLUTAMINASES) that is activated by THROMBIN and CALCIUM to form FACTOR XIIIA. It is important for stabilizing the formation of the fibrin polymer (clot) which culminates the coagulation cascade.
The time required by whole blood to produce a visible clot.
Activated form of factor XI. In the intrinsic pathway, Factor XI is activated to XIa by factor XIIa in the presence of cofactor HMWK; (HIGH MOLECULAR WEIGHT KININOGEN). Factor XIa then activates factor IX to factor IXa in the presence of calcium.
Blood-coagulation factor VIII. Antihemophilic factor that is part of the factor VIII/von Willebrand factor complex. Factor VIII is produced in the liver and acts in the intrinsic pathway of blood coagulation. It serves as a cofactor in factor X activation and this action is markedly enhanced by small amounts of thrombin.
The natural enzymatic dissolution of FIBRIN.
Substances, usually endogenous, that act as inhibitors of blood coagulation. They may affect one or multiple enzymes throughout the process. As a group, they also inhibit enzymes involved in processes other than blood coagulation, such as those from the complement system, fibrinolytic enzyme system, blood cells, and bacteria.
Agents that cause clotting.
A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily.
The process which spontaneously arrests the flow of BLOOD from vessels carrying blood under pressure. It is accomplished by contraction of the vessels, adhesion and aggregation of formed blood elements (eg. ERYTHROCYTE AGGREGATION), and the process of BLOOD COAGULATION.
A vitamin-K dependent zymogen present in the blood, which, upon activation by thrombin and thrombomodulin exerts anticoagulant properties by inactivating factors Va and VIIIa at the rate-limiting steps of thrombin formation.
Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products.
Heat- and storage-labile plasma glycoprotein which accelerates the conversion of prothrombin to thrombin in blood coagulation. Factor V accomplishes this by forming a complex with factor Xa, phospholipid, and calcium (prothrombinase complex). Deficiency of factor V leads to Owren's disease.
Activated form of factor IX. This activation can take place via the intrinsic pathway by the action of factor XIa and calcium, or via the extrinsic pathway by the action of factor VIIa, thromboplastin, and calcium. Factor IXa serves to activate factor X to Xa by cleaving the arginyl-leucine peptide bond in factor X.
Starches that have been chemically modified so that a percentage of OH groups are substituted with 2-hydroxyethyl ether groups.
Clotting time of PLASMA mixed with a THROMBIN solution. It is a measure of the conversion of FIBRINOGEN to FIBRIN, which is prolonged by AFIBRINOGENEMIA, abnormal fibrinogen, or the presence of inhibitory substances, e.g., fibrin-fibrinogen degradation products, or HEPARIN. BATROXOBIN, a thrombin-like enzyme unaffected by the presence of heparin, may be used in place of thrombin.
Activated form of factor XII. In the initial event in the intrinsic pathway of blood coagulation, kallikrein (with cofactor HIGH MOLECULAR WEIGHT KININOGEN) cleaves factor XII to XIIa. Factor XIIa is then further cleaved by kallikrein, plasmin, and trypsin to yield smaller factor XII fragments (Hageman-Factor fragments). These fragments increase the activity of prekallikrein to kallikrein but decrease the procoagulant activity of factor XII.
Agents that prevent clotting.
A protein derived from FIBRINOGEN in the presence of THROMBIN, which forms part of the blood clot.
Any liquid used to replace blood plasma, usually a saline solution, often with serum albumins, dextrans or other preparations. These substances do not enhance the oxygen- carrying capacity of blood, but merely replace the volume. They are also used to treat dehydration.
Stable blood coagulation factor activated by contact with the subendothelial surface of an injured vessel. Along with prekallikrein, it serves as the contact factor that initiates the intrinsic pathway of blood coagulation. Kallikrein activates factor XII to XIIa. Deficiency of factor XII, also called the Hageman trait, leads to increased incidence of thromboembolic disease. Mutations in the gene for factor XII that appear to increase factor XII amidolytic activity are associated with HEREDITARY ANGIOEDEMA TYPE III.
Stable blood coagulation factor involved in the intrinsic pathway. The activated form XIa activates factor IX to IXa. Deficiency of factor XI is often called hemophilia C.
A lipid cofactor that is required for normal blood clotting. Several forms of vitamin K have been identified: VITAMIN K 1 (phytomenadione) derived from plants, VITAMIN K 2 (menaquinone) from bacteria, and synthetic naphthoquinone provitamins, VITAMIN K 3 (menadione). Vitamin K 3 provitamins, after being alkylated in vivo, exhibit the antifibrinolytic activity of vitamin K. Green leafy vegetables, liver, cheese, butter, and egg yolk are good sources of vitamin K.
A hereditary deficiency of blood coagulation factor XI (also known as plasma thromboplastin antecedent or PTA or antihemophilic factor C) resulting in a systemic blood-clotting defect called hemophilia C or Rosenthal's syndrome, that may resemble classical hemophilia.
Endogenous factors and drugs that directly inhibit the action of THROMBIN, usually by blocking its enzymatic activity. They are distinguished from INDIRECT THROMBIN INHIBITORS, such as HEPARIN, which act by enhancing the inhibitory effects of antithrombins.
An absence or reduced level of blood coagulation factor XII. It normally occurs in the absence of patient or family history of hemorrhagic disorders and is marked by prolonged clotting time.
Soluble protein fragments formed by the proteolytic action of plasmin on fibrin or fibrinogen. FDP and their complexes profoundly impair the hemostatic process and are a major cause of hemorrhage in intravascular coagulation and fibrinolysis.
Activated form of factor VIII. The B-domain of factor VIII is proteolytically cleaved by thrombin to form factor VIIIa. Factor VIIIa exists as a non-covalent dimer in a metal-linked (probably calcium) complex and functions as a cofactor in the enzymatic activation of factor X by factor IXa. Factor VIIIa is similar in structure and generation to factor Va.
Formation and development of a thrombus or blood clot in the blood vessel.
Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation.
Activated form of factor V. It is an essential cofactor for the activation of prothrombin catalyzed by factor Xa.
A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts.
A cell surface glycoprotein of endothelial cells that binds thrombin and serves as a cofactor in the activation of protein C and its regulation of blood coagulation.
The classic hemophilia resulting from a deficiency of factor VIII. It is an inherited disorder of blood coagulation characterized by a permanent tendency to hemorrhage.
Found in various tissues, particularly in four blood-clotting proteins including prothrombin, in kidney protein, in bone protein, and in the protein present in various ectopic calcifications.
The most common mineral of a group of hydrated aluminum silicates, approximately H2Al2Si2O8-H2O. It is prepared for pharmaceutical and medicinal purposes by levigating with water to remove sand, etc. (From Merck Index, 11th ed) The name is derived from Kao-ling (Chinese: "high ridge"), the original site. (From Grant & Hackh's Chemical Dictionary, 5th ed)
The vitamin K-dependent cofactor of activated PROTEIN C. Together with protein C, it inhibits the action of factors VIIIa and Va. A deficiency in protein S; (PROTEIN S DEFICIENCY); can lead to recurrent venous and arterial thrombosis.
A method of tissue ablation and bleeding control that uses ARGON plasma (ionized argon gas) to deliver a current of thermocoagulating energy to the area of tissue to be coagulated.
A deficiency of blood coagulation factor IX inherited as an X-linked disorder. (Also known as Christmas Disease, after the first patient studied in detail, not the holy day.) Historical and clinical features resemble those in classic hemophilia (HEMOPHILIA A), but patients present with fewer symptoms. Severity of bleeding is usually similar in members of a single family. Many patients are asymptomatic until the hemostatic system is stressed by surgery or trauma. Treatment is similar to that for hemophilia A. (From Cecil Textbook of Medicine, 19th ed, p1008)
Hemorrhagic and thrombotic disorders that occur as a consequence of inherited abnormalities in blood coagulation.
Absence or reduced levels of PROTHROMBIN in the blood.
Hemorrhagic and thrombotic disorders resulting from abnormalities or deficiencies of coagulation proteins.
A plasma protein which is the precursor of kallikrein. Plasma that is deficient in prekallikrein has been found to be abnormal in thromboplastin formation, kinin generation, evolution of a permeability globulin, and plasmin formation. The absence of prekallikrein in plasma leads to Fletcher factor deficiency, a congenital disease.
Two small peptide chains removed from the N-terminal segment of the alpha chains of fibrinogen by the action of thrombin during the blood coagulation process. Each peptide chain contains 18 amino acid residues. In vivo, fibrinopeptide A is used as a marker to determine the rate of conversion of fibrinogen to fibrin by thrombin.
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
A nutritional condition produced by a deficiency of VITAMIN K in the diet, characterized by an increased tendency to hemorrhage (HEMORRHAGIC DISORDERS). Such bleeding episodes may be particularly severe in newborn infants. (From Cecil Textbook of Medicine, 19th ed, p1182)
A series of progressive, overlapping events, triggered by exposure of the PLATELETS to subendothelial tissue. These events include shape change, adhesiveness, aggregation, and release reactions. When carried through to completion, these events lead to the formation of a stable hemostatic plug.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
Exogenous or endogenous compounds which inhibit SERINE ENDOPEPTIDASES.
The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS.
Blood coagulation disorder usually inherited as an autosomal recessive trait, though it can be acquired. It is characterized by defective activity in both the intrinsic and extrinsic pathways, impaired thromboplastin time, and impaired prothrombin consumption.
A family of snakes comprising three subfamilies: Azemiopinae (the mountain viper, the sole member of this subfamily), Viperinae (true vipers), and Crotalinae (pit vipers). They are widespread throughout the world, being found in the United States, Central and South America, Europe, Asia and Africa. Their venoms act on the blood (hemotoxic) as compared to the venom of elapids which act on the nervous system (neurotoxic). (Goin, Goin, and Zug, Introduction to Herpetology, 3d ed, pp333-36)
Transglutaminases catalyze cross-linking of proteins at a GLUTAMINE in one chain with LYSINE in another chain. They include keratinocyte transglutaminase (TGM1 or TGK), tissue transglutaminase (TGM2 or TGC), plasma transglutaminase involved with coagulation (FACTOR XIII and FACTOR XIIIa), hair follicle transglutaminase, and prostate transglutaminase. Although structures differ, they share an active site (YGQCW) and strict CALCIUM dependence.
The use of green light-producing LASERS to stop bleeding. The green light is selectively absorbed by HEMOGLOBIN, thus triggering BLOOD COAGULATION.
Agents acting to arrest the flow of blood. Absorbable hemostatics arrest bleeding either by the formation of an artificial clot or by providing a mechanical matrix that facilitates clotting when applied directly to the bleeding surface. These agents function more at the capillary level and are not effective at stemming arterial or venous bleeding under any significant intravascular pressure.
The parts of a macromolecule that directly participate in its specific combination with another molecule.
Bleeding or escape of blood from a vessel.
A 3.5 per cent colloidal solution containing urea-cross-linked polymerized peptides. It has a molecular weight of approximately 35,000 and is prepared from gelatin and electrolytes. The polymeric solution is used as a plasma expander.
The rate dynamics in chemical or physical systems.
Proteins prepared by recombinant DNA technology.
Procedures using an electrically heated wire or scalpel to treat hemorrhage (e.g., bleeding ulcers) and to ablate tumors, mucosal lesions, and refractory arrhythmias. It is different from ELECTROSURGERY which is used more for cutting tissue than destroying and in which the patient is part of the electric circuit.
A family of ark shell mollusks, in the class BIVALVIA. They have soft bodies with platelike GILLS enclosed within two shells hinged together.
Proteolytic enzymes from the serine endopeptidase family found in normal blood and urine. Specifically, Kallikreins are potent vasodilators and hypotensives and increase vascular permeability and affect smooth muscle. They act as infertility agents in men. Three forms are recognized, PLASMA KALLIKREIN (EC, TISSUE KALLIKREIN (EC, and PROSTATE-SPECIFIC ANTIGEN (EC
A member of the serpin superfamily found in plasma that inhibits the lysis of fibrin clots which are induced by plasminogen activator. It is a glycoprotein, molecular weight approximately 70,000 that migrates in the alpha 2 region in immunoelectrophoresis. It is the principal plasmin inactivator in blood, rapidly forming a very stable complex with plasmin.
An autosomal recessive characteristic or a coagulation disorder acquired in association with VITAMIN K DEFICIENCY. FACTOR VII is a Vitamin K dependent glycoprotein essential to the extrinsic pathway of coagulation.
A disorder of HEMOSTASIS in which there is a tendency for the occurrence of THROMBOSIS.
The number of PLATELETS per unit volume in a sample of venous BLOOD.
Physiologically inactive substances that can be converted to active enzymes.
Any member of the group of ENDOPEPTIDASES containing at the active site a serine residue involved in catalysis.
Endogenous peptides present in most body fluids. Certain enzymes convert them to active KININS which are involved in inflammation, blood clotting, complement reactions, etc. Kininogens belong to the cystatin superfamily. They are cysteine proteinase inhibitors. HIGH-MOLECULAR-WEIGHT KININOGEN; (HMWK); is split by plasma kallikrein to produce BRADYKININ. LOW-MOLECULAR-WEIGHT KININOGEN; (LMWK); is split by tissue kallikrein to produce KALLIDIN.
Lipid-protein complexes involved in the transportation and metabolism of lipids in the body. They are spherical particles consisting of a hydrophobic core of TRIGLYCERIDES and CHOLESTEROL ESTERS surrounded by a layer of hydrophilic free CHOLESTEROL; PHOSPHOLIPIDS; and APOLIPOPROTEINS. Lipoproteins are classified by their varying buoyant density and sizes.
Agents that prevent fibrinolysis or lysis of a blood clot or thrombus. Several endogenous antiplasmins are known. The drugs are used to control massive hemorrhage and in other coagulation disorders.
A peptidohydrolytic enzyme that is formed from PREKALLIKREIN by FACTOR XIIA. It activates FACTOR XII; FACTOR VII; and PLASMINOGEN. It is selective for both ARGININE and to a lesser extent LYSINE bonds. EC
Limbless REPTILES of the suborder Serpentes.
Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques.
Duration of blood flow after skin puncture. This test is used as a measure of capillary and platelet function.
Enzymes that catalyze the joining of two molecules by the formation of a carbon-carbon bond. These are the carboxylating enzymes and are mostly biotinyl-proteins. EC 6.4.
The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments.
A thrombin receptor subtype that couples to HETEROTRIMERIC GTP-BINDING PROTEINS resulting in the activation of a variety of signaling mechanisms including decreased intracellular CYCLIC AMP, increased TYPE C PHOSPHOLIPASES and increased PHOSPHOLIPASE A2.
A plant genus of the family MORACEAE. Puag-haad extract, from A. lakoocha, contains STILBENES and related 4-substituted RESORCINOLS.
Reduction of blood viscosity usually by the addition of cell free solutions. Used clinically (1) in states of impaired microcirculation, (2) for replacement of intraoperative blood loss without homologous blood transfusion, and (3) in cardiopulmonary bypass and hypothermia.
Derivatives of phosphatidic acids in which the phosphoric acid is bound in ester linkage to a serine moiety. Complete hydrolysis yields 1 mole of glycerol, phosphoric acid and serine and 2 moles of fatty acids.
GLYCOSPHINGOLIPIDS with a sulfate group esterified to one of the sugar groups.
Precursor of plasmin (FIBRINOLYSIN). It is a single-chain beta-globulin of molecular weight 80-90,000 found mostly in association with fibrinogen in plasma; plasminogen activators change it to fibrinolysin. It is used in wound debriding and has been investigated as a thrombolytic agent.
Activated form of FACTOR XIII, a transglutaminase, which stabilizes the formation of the fibrin polymer (clot) culminating the blood coagulation cascade.
Lipids containing one or more phosphate groups, particularly those derived from either glycerol (phosphoglycerides see GLYCEROPHOSPHOLIPIDS) or sphingosine (SPHINGOLIPIDS). They are polar lipids that are of great importance for the structure and function of cell membranes and are the most abundant of membrane lipids, although not stored in large amounts in the system.
A high-molecular-weight plasma protein, produced by endothelial cells and megakaryocytes, that is part of the factor VIII/von Willebrand factor complex. The von Willebrand factor has receptors for collagen, platelets, and ristocetin activity as well as the immunologically distinct antigenic determinants. It functions in adhesion of platelets to collagen and hemostatic plug formation. The prolonged bleeding time in VON WILLEBRAND DISEASES is due to the deficiency of this factor.
Serum proteins that inhibit, antagonize, or inactivate COMPLEMENT C1 or its subunits.
Amidines substituted with a benzene group. Benzamidine and its derivatives are known as peptidase inhibitors.
An arthropod subclass (Xiphosura) comprising the North American (Limulus) and Asiatic (Tachypleus) genera of horseshoe crabs.
Elements of limited time intervals, contributing to particular results or situations.
Spontaneous or near spontaneous bleeding caused by a defect in clotting mechanisms (BLOOD COAGULATION DISORDERS) or another abnormality causing a structural flaw in the blood vessels (HEMOSTATIC DISORDERS).
A family of proteinase-activated receptors that are specific for THROMBIN. They are found primarily on PLATELETS and on ENDOTHELIAL CELLS. Activation of thrombin receptors occurs through the proteolytic action of THROMBIN, which cleaves the N-terminal peptide from the receptor to reveal a new N-terminal peptide that is a cryptic ligand for the receptor. The receptors signal through HETEROTRIMERIC GTP-BINDING PROTEINS. Small synthetic peptides that contain the unmasked N-terminal peptide sequence can also activate the receptor in the absence of proteolytic activity.
Single-chain polypeptides of about 65 amino acids (7 kDa) from LEECHES that have a neutral hydrophobic N terminus, an acidic hydrophilic C terminus, and a compact, hydrophobic core region. Recombinant hirudins lack tyr-63 sulfation and are referred to as 'desulfato-hirudins'. They form a stable non-covalent complex with ALPHA-THROMBIN, thereby abolishing its ability to cleave FIBRINOGEN.
Hydrolases that specifically cleave the peptide bonds found in PROTEINS and PEPTIDES. Examples of sub-subclasses for this group include EXOPEPTIDASES and ENDOPEPTIDASES.
Venoms from snakes of the subfamily Crotalinae or pit vipers, found mostly in the Americas. They include the rattlesnake, cottonmouth, fer-de-lance, bushmaster, and American copperhead. Their venoms contain nontoxic proteins, cardio-, hemo-, cyto-, and neurotoxins, and many enzymes, especially phospholipases A. Many of the toxins have been characterized.
Proteins synthesized by organisms belonging to the phylum ARTHROPODA. Included in this heading are proteins from the subdivisions ARACHNIDA; CRUSTACEA; and HORSESHOE CRABS. Note that a separate heading for INSECT PROTEINS is listed under this heading.
Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures.
A fused four ring compound occurring free or combined in galls. Isolated from the kino of Eucalyptus maculata Hook and E. Hemipholia F. Muell. Activates Factor XII of the blood clotting system which also causes kinin release; used in research and as a dye.
Inflammation of a vein associated with a blood clot (THROMBUS).
Cephalosporin antibiotic, partly plasma-bound, that is effective against gram-negative and gram-positive organisms.
Hormones produced by invertebrates, usually insects, mollusks, annelids, and helminths.
The sum of the weight of all the atoms in a molecule.
Proteins that are present in blood serum, including SERUM ALBUMIN; BLOOD COAGULATION FACTORS; and many other types of proteins.
Solutions or mixtures of toxic and nontoxic substances elaborated by snake (Ophidia) salivary glands for the purpose of killing prey or disabling predators and delivered by grooved or hollow fangs. They usually contain enzymes, toxins, and other factors.
The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain).
A family of soil bacteria. It also includes some parasitic forms.
The residual portion of BLOOD that is left after removal of BLOOD CELLS by CENTRIFUGATION without prior BLOOD COAGULATION.
Domesticated bovine animals of the genus Bos, usually kept on a farm or ranch and used for the production of meat or dairy products or for heavy labor.
The process whereby PLATELETS adhere to something other than platelets, e.g., COLLAGEN; BASEMENT MEMBRANE; MICROFIBRILS; or other "foreign" surfaces.
A biosensing technique in which biomolecules capable of binding to specific analytes or ligands are first immobilized on one side of a metallic film. Light is then focused on the opposite side of the film to excite the surface plasmons, that is, the oscillations of free electrons propagating along the film's surface. The refractive index of light reflecting off this surface is measured. When the immobilized biomolecules are bound by their ligands, an alteration in surface plasmons on the opposite side of the film is created which is directly proportional to the change in bound, or adsorbed, mass. Binding is measured by changes in the refractive index. The technique is used to study biomolecular interactions, such as antigen-antibody binding.
Arginine derivative which is a substrate for many proteolytic enzymes. As a substrate for the esterase from the first component of complement, it inhibits the action of C(l) on C(4).
A class of receptors that are activated by the action of PROTEINASES. The most notable examples are the THROMBIN RECEPTORS. The receptors contain cryptic ligands that are exposed upon the selective proteolysis of specific N-terminal cleavage sites.
Venoms from SNAKES of the viperid family. They tend to be less toxic than elapid or hydrophid venoms and act mainly on the vascular system, interfering with coagulation and capillary membrane integrity and are highly cytotoxic. They contain large amounts of several enzymes, other factors, and some toxins.
An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.
An infant born at or after 42 weeks of gestation.
Single pavement layer of cells which line the luminal surface of the entire vascular system and regulate the transport of macromolecules and blood components.
A genus of snakes of the family VIPERIDAE. It is distributed in West Pakistan, most of India, Burma, Ceylon, Thailand, southeast China, Taiwan, and a few islands of Indonesia. It hisses loudly when disturbed and strikes with great force and speed. Very prolific, it gives birth to 20-60 young. This viper is the leading cause of snakebite in India and Burma. (Moore: Poisonous Snakes of the World, 1980, p127)
Poisonous animal secretions forming fluid mixtures of many different enzymes, toxins, and other substances. These substances are produced in specialized glands and secreted through specialized delivery systems (nematocysts, spines, fangs, etc.) for disabling prey or predator.
Substances that display the physical properties of ELASTICITY and VISCOSITY. The dual-nature of these substances causes them to resist applied forces in a time-dependent manner.
Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN.
The formation or presence of a blood clot (THROMBUS) within a vein.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
The level of protein structure in which combinations of secondary protein structures (alpha helices, beta sheets, loop regions, and motifs) pack together to form folded shapes called domains. Disulfide bridges between cysteines in two different parts of the polypeptide chain along with other interactions between the chains play a role in the formation and stabilization of tertiary structure. Small proteins usually consist of only one domain but larger proteins may contain a number of domains connected by segments of polypeptide chain which lack regular secondary structure.
Electrophoresis in which a polyacrylamide gel is used as the diffusion medium.
Linear polymers in which orthophosphate residues are linked with energy-rich phosphoanhydride bonds. They are found in plants, animals, and microorganisms.
A genus of venomous snakes of the subfamily Crotalinae. Twelve species of this genus are found in North and Central America and Asia. Agkistrodon contortrix is the copperhead, A. piscivorus, the cottonmouth. The former is named for its russet or orange-brown color, the latter for the white interior of its mouth. (Goin, Goin, and Zug, Introduction to Herpetology, 3d ed, p336; Moore, Poisonous Snakes of the World, 1980, p75)
A clinical condition resulting from repeated physical and psychological injuries inflicted on a child by the parents or caregivers.
Extracellular vesicles generated by the shedding of CELL MEMBRANE blebs.
Important modulators of the activity of plasminogen activators. The inhibitors belong to the serpin family of proteins and inhibit both the tissue-type and urokinase-type plasminogen activators.
A product of the lysis of plasminogen (profibrinolysin) by PLASMINOGEN activators. It is composed of two polypeptide chains, light (B) and heavy (A), with a molecular weight of 75,000. It is the major proteolytic enzyme involved in blood clot retraction or the lysis of fibrin and quickly inactivated by antiplasmins.
Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme.
A genus of poisonous snakes of the VIPERIDAE family. About 50 species are known and all are found in tropical America and southern South America. Bothrops atrox is the fer-de-lance and B. jararaca is the jararaca. (Goin, Goin, and Zug, Introduction to Herpetology, 3d ed, p336)
Proteins and peptides found in SALIVA and the SALIVARY GLANDS. Some salivary proteins such as ALPHA-AMYLASES are enzymes, but their composition varies in different individuals.
A member of the serpin family of proteins. It inhibits both the tissue-type and urokinase-type plasminogen activators.
Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream.
Conjugated protein-carbohydrate compounds including mucins, mucoid, and amyloid glycoproteins.
The coagulation of tissue by an intense beam of light, including laser (LASER COAGULATION). In the eye it is used in the treatment of retinal detachments, retinal holes, aneurysms, hemorrhages, and malignant and benign neoplasms. (Dictionary of Visual Science, 3d ed)
A genus of leguminous shrubs or trees, mainly tropical, yielding useful compounds such as ALKALOIDS and PLANT LECTINS.
The internal resistance of the BLOOD to shear forces. The in vitro measure of whole blood viscosity is of limited clinical utility because it bears little relationship to the actual viscosity within the circulation, but an increase in the viscosity of circulating blood can contribute to morbidity in patients suffering from disorders such as SICKLE CELL ANEMIA and POLYCYTHEMIA.
A protein of the annexin family isolated from human PLACENTA and other tissues. It inhibits cytosolic PHOSPHOLIPASE A2, and displays anticoagulant activity.
The species Oryctolagus cuniculus, in the family Leporidae, order LAGOMORPHA. Rabbits are born in burrows, furless, and with eyes and ears closed. In contrast with HARES, rabbits have 22 chromosome pairs.
A single-chain polypeptide derived from bovine tissues consisting of 58 amino-acid residues. It is an inhibitor of proteolytic enzymes including CHYMOTRYPSIN; KALLIKREIN; PLASMIN; and TRYPSIN. It is used in the treatment of HEMORRHAGE associated with raised plasma concentrations of plasmin. It is also used to reduce blood loss and transfusion requirements in patients at high risk of major blood loss during and following open heart surgery with EXTRACORPOREAL CIRCULATION. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995)
The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups.
A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases.
The study of fluid channels and chambers of tiny dimensions of tens to hundreds of micrometers and volumes of nanoliters or picoliters. This is of interest in biological MICROCIRCULATION and used in MICROCHEMISTRY and INVESTIGATIVE TECHNIQUES.
Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment.
A deficiency or absence of FIBRINOGEN in the blood.
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.
The relationship between the dose of an administered drug and the response of the organism to the drug.
A family of serine proteinase inhibitors which are similar in amino acid sequence and mechanism of inhibition, but differ in their specificity toward proteolytic enzymes. This family includes alpha 1-antitrypsin, angiotensinogen, ovalbumin, antiplasmin, alpha 1-antichymotrypsin, thyroxine-binding protein, complement 1 inactivators, antithrombin III, heparin cofactor II, plasminogen inactivators, gene Y protein, placental plasminogen activator inhibitor, and barley Z protein. Some members of the serpin family may be substrates rather than inhibitors of SERINE ENDOPEPTIDASES, and some serpins occur in plants where their function is not known.
A sulfated pentosyl polysaccharide with heparin-like properties.
A product formed from skin, white connective tissue, or bone COLLAGEN. It is used as a protein food adjuvant, plasma substitute, hemostatic, suspending agent in pharmaceutical preparations, and in the manufacturing of capsules and suppositories.
OXIDOREDUCTASES which mediate vitamin K metabolism by converting inactive vitamin K 2,3-epoxide to active vitamin K.
A di-isopropyl-fluorophosphate which is an irreversible cholinesterase inhibitor used to investigate the NERVOUS SYSTEM.
A basic element found in nearly all organized tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes.
Laboratory and other services provided to patients at the bedside. These include diagnostic and laboratory testing using automated information entry.
A group of simple proteins that yield basic amino acids on hydrolysis and that occur combined with nucleic acid in the sperm of fish. Protamines contain very few kinds of amino acids. Protamine sulfate combines with heparin to form a stable inactive complex; it is used to neutralize the anticoagulant action of heparin in the treatment of heparin overdose. (From Merck Index, 11th ed; Martindale, The Extra Pharmacopoeia, 30th ed, p692)
Serine proteinase inhibitors which inhibit trypsin. They may be endogenous or exogenous compounds.
A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances.
The degree of similarity between sequences of amino acids. This information is useful for the analyzing genetic relatedness of proteins and species.
The study of crystal structure using X-RAY DIFFRACTION techniques. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)
A group of substances similar to VITAMIN K 1 which contains a ring of 2-methyl-1,4-naphthoquinione and an isoprenoid side chain of varying number of isoprene units. In vitamin K 2, each isoprene unit contains a double bond. They are produced by bacteria including the normal intestinal flora.
The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements.
A foul-smelling diamine formed by bacterial decarboxylation of lysine.
Any of various animals that constitute the family Suidae and comprise stout-bodied, short-legged omnivorous mammals with thick skin, usually covered with coarse bristles, a rather long mobile snout, and small tail. Included are the genera Babyrousa, Phacochoerus (wart hogs), and Sus, the latter containing the domestic pig (see SUS SCROFA).
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
A salt used to replenish calcium levels, as an acid-producing diuretic, and as an antidote for magnesium poisoning.
A characteristic feature of enzyme activity in relation to the kind of substrate on which the enzyme or catalytic molecule reacts.
Family of calcium- and phospholipid-binding proteins which are structurally related and exhibit immunological cross-reactivity. Each member contains four homologous 70-kDa repeats. The annexins are differentially distributed in vertebrate tissues (and lower eukaryotes) and appear to be involved in MEMBRANE FUSION and SIGNAL TRANSDUCTION.
The volume of packed RED BLOOD CELLS in a blood specimen. The volume is measured by centrifugation in a tube with graduated markings, or with automated blood cell counters. It is an indicator of erythrocyte status in disease. For example, ANEMIA shows a low value; POLYCYTHEMIA, a high value.
A deficiency of blood coagulation FACTOR XIII or fibrin stabilizing factor (FSF) that prevents blood clot formation and results in a clinical hemorrhagic diathesis.
Two-phase systems in which one is uniformly dispersed in another as particles small enough so they cannot be filtered or will not settle out. The dispersing or continuous phase or medium envelops the particles of the discontinuous phase. All three states of matter can form colloids among each other.
Venous vessels in the umbilical cord. They carry oxygenated, nutrient-rich blood from the mother to the FETUS via the PLACENTA. In humans, there is normally one umbilical vein.
Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles.
A subfamily in the family MURIDAE, comprising the hamsters. Four of the more common genera are Cricetus, CRICETULUS; MESOCRICETUS; and PHODOPUS.
Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY).
Peptides composed of between two and twelve amino acids.
Control of bleeding during or after surgery.
Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc.
An antiphospholipid antibody found in association with systemic lupus erythematosus (LUPUS ERYTHEMATOSUS, SYSTEMIC;), ANTIPHOSPHOLIPID SYNDROME; and in a variety of other diseases as well as in healthy individuals. In vitro, the antibody interferes with the conversion of prothrombin to thrombin and prolongs the partial thromboplastin time. In vivo, it exerts a procoagulant effect resulting in thrombosis mainly in the larger veins and arteries. It further causes obstetrical complications, including fetal death and spontaneous abortion, as well as a variety of hematologic and neurologic complications.
The arrangement of two or more amino acid or base sequences from an organism or organisms in such a way as to align areas of the sequences sharing common properties. The degree of relatedness or homology between the sequences is predicted computationally or statistically based on weights assigned to the elements aligned between the sequences. This in turn can serve as a potential indicator of the genetic relatedness between the organisms.
Established cell cultures that have the potential to propagate indefinitely.
Chemical groups containing the covalent disulfide bonds -S-S-. The sulfur atoms can be bound to inorganic or organic moieties.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation.
Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES).

Exosites 1 and 2 are essential for protection of fibrin-bound thrombin from heparin-catalyzed inhibition by antithrombin and heparin cofactor II. (1/3556)

Assembly of ternary thrombin-heparin-fibrin complexes, formed when fibrin binds to exosite 1 on thrombin and fibrin-bound heparin binds to exosite 2, produces a 58- and 247-fold reduction in the heparin-catalyzed rate of thrombin inhibition by antithrombin and heparin cofactor II, respectively. The greater reduction for heparin cofactor II reflects its requirement for access to exosite 1 during the inhibitory process. Protection from inhibition by antithrombin and heparin cofactor II requires ligation of both exosites 1 and 2 because minimal protection is seen when exosite 1 variants (gamma-thrombin and thrombin Quick 1) or an exosite 2 variant (Arg93 --> Ala, Arg97 --> Ala, and Arg101 --> Ala thrombin) is substituted for thrombin. Likewise, the rate of thrombin inhibition by the heparin-independent inhibitor, alpha1-antitrypsin Met358 --> Arg, is decreased less than 2-fold in the presence of soluble fibrin and heparin. In contrast, thrombin is protected from inhibition by a covalent antithrombin-heparin complex, suggesting that access of heparin to exosite 2 of thrombin is hampered when ternary complex formation occurs. These results reveal the importance of exosites 1 and 2 of thrombin in assembly of the ternary complex and the subsequent protection of thrombin from inhibition by heparin-catalyzed inhibitors.  (+info)

Nonanticoagulant heparin prevents coronary endothelial dysfunction after brief ischemia-reperfusion injury in the dog. (2/3556)

BACKGROUND: Coronary endothelial dysfunction after brief ischemia-reperfusion (IR) remains a clinical problem. We investigated the role of heparin and N-acetylheparin, a nonanticoagulant heparin derivative, in modulating coronary endothelial function after IR injury, with an emphasis on defining the role of the nitric oxide (NO)-cGMP pathway in the heparin-mediated effect. METHODS AND RESULTS: Male mongrel dogs were surgically instrumented, and the effects of both bovine heparin and N-acetylheparin on coronary endothelial vasomotor function, expressed as percent change from baseline flow after acetylcholine challenge, were studied after 15 minutes of regional ischemia of the left anterior descending artery (LAD) followed by 120 minutes of reperfusion. In dogs treated with placebo (saline), coronary vasomotor function was significantly (P+info)

Distinct contributions of residue 192 to the specificity of coagulation and fibrinolytic serine proteases. (3/3556)

Archetypal members of the chymotrypsin family of serine proteases, such as trypsin, chymotrypsin, and elastase, exhibit relatively broad substrate specificity. However, the successful development of efficient proteolytic cascades, such as the blood coagulation and fibrinolytic systems, required the evolution of proteases that displayed restricted specificity. Tissue-type plasminogen activator (t-PA), for example, possesses exquisitely stringent substrate specificity, and the molecular basis of this important biochemical property of t-PA remains obscure. Previous investigations of related serine proteases, which participate in the blood coagulation cascade, have focused attention on the residue that occupies position 192 (chymotrypsin numbering system), which plays a pivotal role in determining both the inhibitor and substrate specificity of these enzymes. Consequently, we created and characterized the kinetic properties of new variants of t-PA that contained point mutations at position 192. These studies demonstrated that, unlike in coagulation serine proteases, Gln-192 does not contribute significantly to the substrate or inhibitor specificity of t-PA in physiologically relevant reactions. Replacement of Gln-192 with a glutamic acid residue did, however, decrease the catalytic efficiency of mature, two-chain t-PA toward plasminogen in the absence of a fibrin co-factor.  (+info)

Age-related changes in blood coagulation and fibrinolysis in mice fed on a high-cholesterol diet. (4/3556)

To investigate the pathogenesis of hyperlipidemia-induced atherosclerosis, we examined age-dependent changes in platelet activity, blood coagulation and fibrinolysis in susceptibility to a high cholesterol diet (HCD) feeding in male ICR mice. Pretreatment of platelet-rich-plasma from HCD feeding mice for 3 days with epinephrine (300 microM) resulted in a marked enhancement of adenosine 5'-diphosphate (ADP: 0.1 microM) or collagen (0.7 microgram/ml)-stimulated aggregation compared with the same in control mice. Yohimbine as alpha 2-adrenergic blocker antagonized these aggregations in a dose-dependent manner. A significant increase in plasma total cholesterol and VLDL (very low-density lipoprotein)-LDL (low-density lipoprotein)-cholesterol and the liver/body weight ratio was observed in mice fed on HCD for 3 months (3-month HCD mice). In the early phase of this experiment, a significant increase in fibrinogen was observed. In the middle phase, increases in the activity of antithrombin III (ATIII) and alpha 2-plasmin inhibitor (alpha 2-Pl) followed. Plasminogen content gradually decreased in both normal diet and HCD mice throughout the experiment. The activity of plasminogen activator inhibitor (PAI) decreased in 3-month HCD mice. Morphological observation of the aortic arch from 3-month HCD mice revealed apparent atheromatous plaques not seen in control mice. These results suggest that 3-month HCD mice can be a convenient hyperlipidemia-induced atherosclerotic model and the changes in platelet activity, coagulation and fibrinolysis in the early phase may be a cause of pathologic changes in this model.  (+info)

PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. (5/3556)

Plasminogen activator inhibitor type-1 (PAI-1) is a major physiological inhibitor of fibrinolysis, with its plasma levels correlating with the risk for myocardial infarction and venous thrombosis. The regulation of PAI-1 transcription by endothelial cells (ECs), a major source of PAI-1, remains incompletely understood. Adipocytes also produce PAI-1, suggesting possible common regulatory pathways between adipocytes and ECs. Peroxisomal proliferator-activated receptor-gamma (PPAR)gamma is a ligand-activated transcription factor that regulates gene expression in response to various mediators such as 15-deoxy-Delta12, 14-prostaglandin J2 (15d-PGJ2) and oxidized linoleic acid (9- and 13-HODE). The present study tested the hypotheses that human ECs express PPARgamma and that this transcriptional activator regulates PAI-1 expression in this cell type. We found that human ECs contain both PPARgamma mRNA and protein. Immunohistochemistry of human carotid arteries also revealed the presence of PPARgamma in ECs. Bovine ECs transfected with a PPAR response element (PPRE)-luciferase construct responded to stimulation by the PPARgamma agonist 15d-PGJ2 in a concentration-dependent manner, suggesting a functional PPARgamma in ECs. Treatment of human ECs with 15d-PGJ2, 9(S)-HODE, or 13(S)-HODE augmented PAI-1 mRNA and protein expression, whereas multiple PPARalpha activators did not change PAI-1 levels. Introduction of increasing amounts of a PPARgamma expression construct in human fibroblasts enhanced PAI-1 secretion from these cells in proportion to the amount of transfected DNA. Thus, ECs express functionally active PPARgamma that regulates PAI-1 expression in ECs. Our results establish a role for PPARgamma in the regulation of EC gene expression, with important implications for the clinical links between obesity and atherosclerosis.  (+info)

Antithrombotic efficacy of thrombin inhibitor L-374,087: intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis. (6/3556)

The small molecule direct thrombin inhibitor L-374,087 was characterized across species in an in vitro activated partial thromboplastin clotting time (aPTT) assay and in vivo in rhesus monkey and dog thrombosis models. In vitro in rhesus, dog, and human plasma, L-374,087 concentrations eliciting 2-fold increases in aPTT were 0.25, 1.9, and 0.28 microM, respectively. In anesthetized rhesus monkeys, 300 microgram/kg bolus plus 12 microgram/kg/min and 300 microgram/kg bolus plus 30 microgram/kg/min L-374,087 i.v. infusions significantly reduced jugular vein thrombus extension, with both regimens limiting venous thrombus extension to 2-fold that of baseline thrombus mass compared with a 5-fold extension observed in the vehicle control group. Antithrombotic efficacy in the rhesus with the lower-dose regimen was achieved with 2.3- to 2.4-fold increases in aPTT and prothrombin time. In a conscious instrumented dog model of electrolytic vessel injury, the oral administration of two 10 mg/kg L-374,087 doses 12 h apart significantly reduced jugular vein thrombus mass, reduced the incidence of and delayed time to occlusive coronary artery thrombosis, and significantly reduced coronary artery thrombus mass and ensuing posterolateral myocardial infarct size. Antithrombotic efficacy in the dog was achieved with 1.6- to 2.0-fold increases in aPTT at 1 to 6 h after oral dosing with L-374,087. These results indicate significant antithrombotic efficacy against both venous and coronary arterial thrombosis with L-374,087 with only moderate elevations in aPTT or prothrombin time. The oral efficacy of L-374,087 characterizes this compound as a prototype for the further development of orally active direct thrombin inhibitors.  (+info)

Risk of clot formation in femoral arterial sheaths maintained overnight for neuroangiographic procedures. (7/3556)

BACKGROUND AND PURPOSE: The purpose of this study was to evaluate the presence of blood clots in femoral arterial sheaths maintained after cerebral angiography and the effect of heparinized saline on clot formation. METHODS: Twenty-three sheaths were evaluated in 18 patients. Sheaths were maintained for 14 to 80 hours (average, 33 hours; median, 24 hours). After the sheaths were removed, they were vigorously flushed with 60 mL of normal saline and the number and size of clots found in each sheath were recorded. Additionally, patients' age, catheter size, presence of heparin, amount of time the sheath was kept in the artery, and patients' coagulation status were recorded. RESULTS: Clots were found in 17 (74%) of the 23 sheaths. Ten catheters had continuous heparin drip, of which seven (70%) sustained clots. Of the 13 sheaths without heparin, 10 sustained clots (77%). The difference was not statistically significant. The average number of clots was 2.2, and the maximal length of clots ranged from 0.5 to 105 mm. No thromboembolic complications associated with sheath placement were encountered in our patient population. CONCLUSION: Blood clots are present in the vast majority of intraarterial sheaths maintained after cerebral angiography. These clots constitute a risk of thromboembolic complications in the event of repeat angiography. Sheath exchange should be considered before obtaining repeat cerebral angiograms.  (+info)

Thrombelastographic changes and early rebleeding in cirrhotic patients with variceal bleeding. (8/3556)

BACKGROUND: Routine coagulation tests do not necessarily reflect haemostasis in vivo in cirrhotic patients, particularly those who have bleeding varices. Thrombelastography (TEG) can provide a global assessment of haemostatic function from initial clot formation to clot dissolution. AIM: To evaluate TEG changes in cirrhotic patients with variceal bleeding and their association with early rebleeding. PATIENTS/METHODS: Twenty cirrhotic patients with active variceal bleeding had serial TEG and routine coagulation tests daily for seven days. The TEG variables before the day of rebleeding (n = 6) were compared with those of patients without rebleeding (n = 14). RESULTS: Baseline characteristics of the rebleeding and non-rebleeding groups were comparable apart from a higher incidence of uncontrolled infection on the day of rebleeding in the rebleeding group (p = 0.007). The patients in the rebleeding group were more hypocoagulable before the day of rebleeding as shown by longer r (42 v 24 mm, p < 0.001) and k (48 v 13 mm, p < 0.001) and smaller a (12 v 38 degrees, p < 0.001) compared with the mean of daily results of the non-rebleeding group. Routine coagulation tests, however, showed no significant differences between the two groups. CONCLUSION: The results of serial TEG measurements suggest that hypocoagulability may be associated with early rebleeding in cirrhotic patients.  (+info)

0070] In this case, the analyzing section 42 determines whether or not the aggregability of the platelets is good depending on whether the shortening width (or delay width) Δt of the blood coagulation time of the sample blood to which the platelet activating agent etc. is added is larger or smaller than the reference value (Δts). Specifically, the analyzing section 42 determines that the aggregability of the platelets is high if the shortening width Δt of the blood coagulation time of the sample blood to which the platelet activating agent is added is larger than the reference value (Δts). Conversely, the analyzing section 42 determines that the aggregability of the platelets is low if the shortening width Δt is smaller than the reference value (Δts). Alternatively, the analyzing section 42 determines that the aggregability of the platelets is high if the delay width Δt of the blood coagulation time of the sample blood to which the platelet inactivating agent is added is larger than the ...
The effects of treadmill exercise on platelet function, blood coagulability and fibrinolytic activity were evaluated in 20 patients with lone atrial fibrillation (AF) and 15 age-matched normal controls (normals). Multistage treadmill exercise up to 8
Platelets play a major role in the complex interactions involved in blood coagulation via multiple mechanisms. As reported in this issue, Schoergenhofer et al. tested the hypothesis that platelet inhibition by prasugrel, a potent platelet P2Y12 ADP receptor antagonist, attenuates the effect of lipopolysaccharide (LPS) on the blood coagulation system in healthy human subjects. LPS, a bacterial product with potent pro-inflammatory and pro-thrombotic effects, plays a central role in sepsis. It activates monocytes and endothelial cells via Toll-like receptor (TLR) 4 and other TLRs to stimulate production of TF and other pro-coagulant molecules, chemokines and cytokines. Treatment with prasugrel did not decrease biomarkers of coagulaion. A better understanding of the relative roles of platelet and coagulation mechanisms in triggering the pro-thrombotic state may lead to more effective antithrombotic strategies. ...
TY - JOUR. T1 - Activation of blood coagulation in autoimmune skin disorders. AU - Cugno, Massimo. AU - Tedeschi, Alberto. AU - Crosti, Carlo. AU - Marzano, Angelo V.. PY - 2009/9. Y1 - 2009/9. N2 - The immune system and blood coagulation are simultaneously activated in several inflammatory systemic disorders, such as lupus erythematosus, rheumatoid arthritis and inflammatory bowel diseases. Proinflammatory cytokines, such as IL-6 and TNF-α, induce the expression of tissue factor, the main initiator of blood coagulation. Activated proteases of coagulation in turn act on protease-activated receptors, inducing the expression of various proinflammatory cytokines. This cross-talk between inflammation and coagulation amplifies and maintains the activation of both systems. This review focuses on three skin disorders: chronic urticaria (CU), which is considered autoimmune in approximately 50% of cases, bullous pemphigoid (BP), which is the prototype of autoimmune blistering disease, and psoriasis, ...
Blood coagulation functions as part of the innate immune system by preventing bacterial invasion and it is critical to stopping blood loss (hemostasis). Coagulation involves the external membrane surface of activated platelets and leukocytes. Using lipidomic, genetic, biochemical, and mathematical modeling approaches, we found that enzymatically oxidized phospholipids (eoxPLs) generated by the activity of leukocyte or platelet lipoxygenases (LOXs) were required for normal hemostasis and promoted coagulation factor activities in a Ca2+- and phosphatidylserine (PS)- dependent manner. In wild-type mice, hydroxyeicosatetraenoic acid-phospholipids (HETE-PLs) enhanced coagulation and restored normal hemostasis in clotting-deficient animals genetically lacking p12-LOX or 12/15-LOX activity. Murine platelets generated 22 eoxPL species, all of which were missing in the absence of p12-LOX. Humans with the thrombotic disorder antiphospholipid syndrome (APS) had statistically significantly increased ...
Research could lead to new therapies. In our not-so-distant evolutionary past, stress often meant imminent danger, and the risk of blood loss, so part of our bodys stress response is to stock-pile blood-clotting factors. Scientists in the Molecular Medicine Partnership Unit (MMPU), a collaboration between the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, and the University of Heidelberg Medical Centre, have discovered how stressed cells boost the production of the key blood-clotting factor, thrombin. Their work, published today in Molecular Cell, shows how cancer cells may be taking advantage of this process, and opens new possibilities for fighting back, not only against cancer but also against septicaemia, where increased blood clotting is still one of the leading causes of death.. Blood clots tend to form more often in the veins of people with cancer, a syndrome first described almost 150 years ago by French physician Armand Trousseau. In recent years, doctors have ...
Background: In recent years, research has been done into various aspects of blood coagulation system, while the effect of exercise on this system has not been studied. Exercise may be able to contribute to the processes of coagulation and fibrinolysis cascades.Aim: To investigate the effect of six months of aerobic exercise on proteins C, S and platelets in sedentary middle-aged women.Methods: In this randomized clinical trial, 19 inactive middle-aged women were randomly divided into two groups: experimental and control. The experimental group attended aerobic exercise with the intensity of 55 to 65% of the heart rate reserve for six months; three sessions per week, each 60 minutes. A Coulter type CO-BASS device measured the coagulation factors. Data were analyzed by SPSS ver. 16, independent and paired t-tests.Results: the mean age was 42.2 ± 3.3 years old and weight 64.0 ± 8.6 kg. Sample were identical and normal confirmed by statistical tests of levene and Shapiro-Willkie (p|0.05). The results of
The process of fibrin formation takes place in two different pathways of the coagulation cascade of the secondary hemostasis. The pathways are the contact activation and the tissue factor pathway.. Contact activation pathway (intrinsic pathway). The step starts with the formation of collagen (Laposata, M. 2011, p. 109).. This step has a minor role in initiating the clot formation process compared to the tissue factor pathway as evidenced by lack of bleeding disorder in patients with severe deficiencies of FXII, prekallikrein, and HMWK.. The course is however, much involved in the process of inflammation.. Tissue factor pathway (extrinsic pathway). This pathway generates the thrombin bust that leads to the release of thrombin from the complex prothrombinase.. Thrombin is a very important component of the coagulation cascade as it activates feedback.. It also activates the other components of the coagulation cascade. The process starts when the blood vessels are damaged (Amy M. K., 2012, p. ...
Haemostasis is a dynamic process to stop bleeding after vessel wall damage. Platelets form a platelet plug via activation, adherence, and aggregation processes. The coagulation proteins are activated one-by-one, cascading towards fibrin polymerization, a process controlled by thrombin generation. Fibrinolysis is the process responsible for fibrin mesh degradation, which is also controlled by thrombin. Besides procoagulant proteins, anticoagulant proteins maintain a balance in the haemostatic system. Measuring platelet count and function can be done as part of the monitoring of haemostasis, while coagulation times are measured to assess the coagulation proteins. Degradation products of fibrin and lysis times give information about fibrinolysis. Point-of-care monitoring provides simple, rapid bedside testing for platelets and for whole blood using viscoelasticity properties. In trauma-induced coagulopathy (TIC) platelet counts and coagulation times are still common practice to evaluate haemostasis, but
R. T. BAILLY 3,814,585 METHOD AND APPARATUS FOR TESTING BLOOD COAGULATION June 4, 1974 Filed Sept. 26. 1972 EVENTUALLY REACHES ZERO FIG. 2 FIG. 3 United States Patent ice 3,814,585 METHOD AND APPARATUS FOR TESTING BLOOD COAGULATION Robert T. Bailly, Hinman Road, Barneveld, NY. 13304 Filed Sept. 26, 1972, Ser. No. 292,399 Int. Cl. G011! 33/16 US. Cl. 23230 B Claims ABSTRACT OF THE DISCLOSURE A freshly drawn sample of venous blood is placed in a container, such as a hypodermic syringe, and a thread is moved lengthwise through the sample until a substantially continuous mass of fibrin and/or red blood cells form thereon, marking the endpoint of the test. The thread is of a material to which blood coagulation substances adhere, preferably a water wettable material such as glass, or plant or animal fibers, e.g., cotton or wool. The thread may be inserted through the needle of the syringe and an electric motor with suitable reduction gearing used to draw the thread through the needle and blood sample ...
The 14-3-3 family of adaptor proteins regulate diverse cellular functions including cell proliferation, metabolism, adhesion and apoptosis. Platelets express numerous 14-3-3 isoforms, including 14-3- z , which has previously been implicated in regulating GPIb a function. Here we show an important role for 14-3-3 z in regulating arterial thrombosis. Interestingly, this thrombosis defect is not related to alterations in von Willebrand factor (VWF)-GPIb adhesive function or platelet activation, but instead associated with reduced platelet phosphatidylserine (PS) exposure and procoagulant function. Decreased PS exposure in 14-3-3 z -deficient platelets is associated with more sustained levels of metabolic ATP and increased mitochondrial respiratory reserve, independent of alterations in cytosolic calcium flux. Reduced platelet PS exposure in 14-3-3 z -deficient mice does not increase bleeding risk, but results in decreased thrombin generation and protection from pulmonary embolism, leading to ...
© 2014 The British Infection Association. Objectives: Human tuberculosis (TB) remains an important cause of death globally. Bangladesh is one of the most affected countries. We aimed to investigate the impact of pulmonary TB on pro- and anticoagulant mechanisms. Methods: This prospective study was conducted in Chittagong, Bangladesh. We performed an in-depth analysis of coagulation activation and inhibition in plasma obtained from 64 patients with primary lung TB and 11 patients with recurrent lung TB and compared these with 37 healthy controls. Additionally, in nine patients coagulation activation was studied in bronchoalveolar lavage fluid (BALF) harvested from the site of infection and compared with BALF from a contralateral unaffected lung subsegment. Results: Relative to uninfected controls, primary and recurrent TB were associated with a systemic net procoagulant state, as indicated by enhanced activation of coagulation (elevated plasma levels of thrombin-antithrombin complexes, D-dimer and
D. Sliding-scale regular insulin every 6 hours. · Question 99. The correct treatment for ankle sprain during the first 48 hours after injury includes:. · Question 100. Prolonged PT suggests:. A.. Platelet abnormality. B.. Abnormality in intrinsic coagulation pathway. C.. Abnormality in extrinsic coagulation pathway. D.. None of the above. Question 101. ·. A patient presenting for an annual physical exam has a BMI of 25 kg/m2 This patient would be classified as:. · Question 102. The most reliable indicator(s) of neurological deficit when assessing a patient with acute low back pain is(are):. · Question 103. Risk factors for Addisons disease include which of the following?. · Question 104. Major depression occurs most often in which of the following conditions?. · Question 105. Which of the following medications increase the risk for metabolic syndrome?. · Question 106. A 27 year old female patient with epilepsy is well controlled with phenytoin (Dilantin). She requests information about ...
Contrary to previous models based on plasma, coagulation processes are currently believed to be mostly cell surface-based, including three overlapping phases: initiation, when tissue factor-expressing cells and microparticles are exposed to plasma; amplification, whereby small amounts of thrombin induce platelet activation and aggregation, and promote activation of factors (F)V, FVIII and FXI on platelet surfaces; and propagation, in which the Xase (tenase) and prothrombinase complexes are formed, producing a burst of thrombin and the cleavage of fibrinogen to fibrin. Thrombin exerts a number of additional biological actions, including platelet activation, amplification and self-inhibition of coagulation, clot stabilisation and anti-fibrinolysis, in processes occurring in the proximity of vessel injury, tightly regulated by a series of inhibitory mechanisms. Classical anticoagulants, including heparin and vitamin K antagonists, typically target multiple coagulation steps. A number of new
In this study, we present a novel modeling approach which combines ordinary differential equation ODE modeling with logical rules to simulate an archetype biochemical network, the human coagulation cascade. The model consisted of five differential equations augmented with several logical rules describing regulatory connections between model components, and unmodeled interactions in the network. This formulation was more than an order of magnitude smaller than current coagulation models, because many of the mechanistic details of coagulation were encoded as logical rules. We estimated an ensemble of likely model parameters N 20 from in vitro extrinsic coagulation data sets, with and without inhibitors, by minimizing the residual between model simulations and experimental measurements using particle swarm optimization PSO. Each parameter set in our ensemble corresponded to a unique particle in the PSO. We then validated the model ensemble using thrombin data sets that were not used during training. The
THEFREEDOMARTICLES.COM Corona Effect Exposed by Doctor; COVID not Viral but Blood Coagulation This doctor exposes the corona effect of cells, showing that COVID is not a viral condition but due to blood coagulation caused by acidosis. . _________________________________________________________
bs0630 portable blood electro coagulation machine price, blood coagulation analyzer or machine automated, roche coaguchek system coagulation analyzers, best price automated single channel boold coagulation, china yste502 fully automatic blood coagulation machine
Synonyms for Coagulation factors in Free Thesaurus. Antonyms for Coagulation factors. 2 synonyms for coagulation: clotting, curdling. What are synonyms for Coagulation factors?
TY - CONF. T1 - Clot waveform analysis. AU - Evrard, Jonathan. AU - Siriez, Romain. AU - Morimont, Laure. AU - Mullier, François. A2 - Dogne, Jean-Michel. A2 - Douxfils, Jonathan. PY - 2018. Y1 - 2018. M3 - Poster. Y2 - 22 November 2018 through 23 November 2018. ER - ...
Blood Coagulation (thrombogenesis) is the intricate process by which blood forms clots. Disorders of coagulation can accelerate to an expanded risk of blee..
FFTAC : Specimen Type: Citrated plasma Collection Container/Tube: Light-blue top (citrate) Specimen Volume: 2 mL Collection Instructions: Draw blood in a light blue-top (Sodium citrate) tube(s). Spin down and send 2 mL citrated plasma frozen in a plastic vial.   Note: Separate specimens must be submitted when multiple tests are ordered.
Schistosomes, parasitic worms that cause the tropical disease schistosomiasis, are able to survive in the hosts bloodstream for up to 30 years. Their survival in this hostile environment without activation of the coagulation system or clearance by the immune system is remarkable. The aim of this thesis is to describe ... read more the strategies used by schistosomes to allow their survival in the circulation. Blood coagulation around the parasite is inhibited at many different levels by schistosomes. In addition, the parasitic surface forms a protective barrier against immune recognition and immune damage. Furthermore, schistosomes have several strategies to inhibit or modulate host immune responses. These different strategies are often a clever combination of mimicking or using host mechanisms for regulation of the immune and haemostatic system and schistosome specific strategies to inhibit host blood coagulation and immune responses or to protect the parasite from immune damage. Insight in ...
Global Blood Coagulation Testing Market Information by instruments (prothrombin time, APTT, thrombo test) by methods (Global test, Local test) by End Users (Hospitals, clinics, Research Institutes) - Forecast to 2027
The response that ensured humans survival was rapid, systemic, and extreme.. STEP I: On the Meaning and Significance of Stress. 1. The heart rate increased to give the body a boost in the supply of energy and oxygen to the heart, lungs, and muscles.. 2. Blood pressure increased as the circulation was redirected from the skin and other non-fighting organs to the heart, lungs, and muscles.. 3. Blood coagulability increased to protect against bleeding to death from possible wounds.. 4. Protection against shock in the event of excessive bleeding left the skin feeling cold and clammy. Shivering, tightening of the skin, and goose ?esh helped to conserve body heat in the event of blood loss.. 5. The body began to sweat to release the heat generated by the work the body was performing to prepare for and engage in fight or flight.. 6. The rate of breathing increased to raise the supply of oxygen to the muscles and help metabolize more glucose for increased energy needs.. 7. There would be a sudden ...
TY - GEN. T1 - Blood coagulation estimation using the method of laser-speckle correlation. AU - Li, Lin. AU - Sytnik, Iuliia D.. AU - Pekker, Yakov S.. AU - Gubarev, Fedor A.. PY - 2019/1/1. Y1 - 2019/1/1. N2 - This work presents the results of clotting time estimation using the method of laser speckle imaging. The method determines the clotting time blood by calculating correlation coefficient between adjacent laser-speckle images. The study was accomplished with two different samples of blood, i.e. with fresh blood and blood with anticoagulant additive. Statistical analyses of the results obtained under the laboratory conditions provides discussion about the improvement of these methods for practical application for the task of clotting time measurements.. AB - This work presents the results of clotting time estimation using the method of laser speckle imaging. The method determines the clotting time blood by calculating correlation coefficient between adjacent laser-speckle images. The study ...
Coagulation proteases, in addition to their role in the regulation of blood coagulation, can modulate intracellular signaling events by activating a subfamily o...
There is a large amount of experimental evidence that supports the concept of an association between blood coagulation and malignant disease. Since several chapters within this volume describe...
When an artery to the heart becomes narrow or blocked due to plaque build-up, doctors may try to surgically widen the artery in a procedure called balloon angioplasty. After surgery, blood clots are more likely to form, raising chances for heart attacks. To avoid this, doctors give blood-thinning medications. Researchers wanted to test the anti-clotting capacity of omega-3s. Fifty-four men and women, average age 63, with stable coronary artery disease and a recent successful balloon angioplasty, took the standard anti-clot medications, aspirin and clopidogrel, with or without 460 mg of EPA plus 380 mg of DHA per day. Compared to those who did not take EPA and DHA, those who did had fewer abnormal blood-clotting factors, better blood-clotting traits, and a more balanced and controlled clotting process. Doctors also observed less oxidative stress in the omega-3 group. Reference: Arteriosclerosis, Thrombosis, and Vascular Biology; 2011, Vol. 31, No. 7, 1696-702 ...
When an artery to the heart becomes narrow or blocked due to plaque build-up, doctors may try to surgically widen the artery in a procedure called balloon angioplasty. After surgery, blood clots are more likely to form, raising chances for heart attacks. To avoid this, doctors give blood-thinning medications. Researchers wanted to test the anti-clotting capacity of omega-3s. Fifty-four men and women, average age 63, with stable coronary artery disease and a recent successful balloon angioplasty, took the standard anti-clot medications, aspirin and clopidogrel, with or without 460 mg of EPA plus 380 mg of DHA per day. Compared to those who did not take EPA and DHA, those who did had fewer abnormal blood-clotting factors, better blood-clotting traits, and a more balanced and controlled clotting process. Doctors also observed less oxidative stress in the omega-3 group. Reference: Arteriosclerosis, Thrombosis, and Vascular Biology; 2011, Vol. 31, No. 7, 1696-702 ...
Haematological and coagulation parameters may help predict COVID-19 disease severity or mortality, according to a retrospective study from China. &ld...
Headline: Bitcoin & Blockchain Searches Exceed Trump! Blockchain Stocks Are Next!. The report, Global Coagulation Testing Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. This report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.. Key players in the global coagulation testing market: Roche Diagnostics, Alere, Abbott Laboratories, and Siemens Healthcare. Other Prominent Vendors in the market are: Accriva Diagnostics, CoaguSense, Diagon, Helena Laboratories, HemoSonics, iLine Microsystems, Medtronic, Micropoint Bioscience, and Sysmex.. Purchase a Copy of the Report @ The analysts forecast the global coagulation testing market to grow at a CAGR of 6.43% during the period 2017-2021. Coagulation testing helps measure the ability of blood to form a clot. Clotting occurs ...
Blood clots are typically a very useful mechanism within the body. When you get a papercut or other minor injury, you may notice that the blood eventually stops flowing. This stoppage happens because of blood clots at the site of the wound, preventing you from losing all of your blood through one small cut. When the blood within your veins forms a clot, however, this same mechanism that usually protects you can turn deadly instead. Blood clots in your veins can break off and travel to important organs, causing a heart attack or stroke, among other issues. It is important to know what the common causes of blood clots are, to find out if you may be at a higher risk for this complication.. ...
Acquired coagulopathy is a relatively uncommon occurrence in acute paediatrics but when it occurs is usually associated with significant underlying pathology and often with critical illness. It can be caused by a number of disease processes but infection, blood loss, iatrogenic causes and liver dysfunction are among the commonest. The blood coagulation cascade is complex and intersects with many other physiological pathways. It is also subject to developmental changes, and normal coagulation and haemostasis change considerably during early life. The diagnosis of abnormal coagulation and when treatment should be initiated is influenced both by age and developmental status and limited by the range of tests routinely available to clinicians. Treatment has predominantly involved transfusion of plasma products (usually fresh frozen plasma and cryoprecipitate) but a number of pharmaceutical and human-derived options are now available. Although plasma products are less frequently transfused than red ...
inhibits neutrophil adhesion to vascular endothelium. 2. Hypertension associated with pregnancy. - resemble deficiency of NO and PG. - possible role of enhancing NO levels via nutritional supp.w/L-arginine. 3. Respiratory disorders. - used via inhalation to newborns w/pulmonary hypertension and ARDS. - decreases pulmonary arterial pressure and improves blood oxygenation. - also used in open trials in adults with ARDS. - may act also act as bronchodilator by relaxing airway smooth muscle. 4. Septic shock. -Urinary excretion of NO3, oxidative product of nitric oxide in 0- bacterial infection. 5. Atherosclerosis. - may act as antioxidant, blocking oxidation of LDL, preventing foam cell formation in the vascular wall. 6. Platelets. -nitric oxide = potent inhibitor of platelet adhesion and aggregation - as in vascular sm.muscle, cGMP mediates protective effect of NO in platelets. -may have additional effect on blood coagulation by enhancing fibrinolysis via effect on plasminogen. 7. Organ ...
Study Coagulation/Anticoagulation and Hemorrhagic/Thrombotic Disorders flashcards from Justin Holmes's University of Colorado Medical School class online, or in Brainscape's iPhone or Android app. ✓ Learn faster with spaced repetition.
In the coagulation system two mechanisms operate that are indispensable to life and normally work in opposite directions, each counterbalancing the other. On the one hand, coagulation involves a thickening of the blood so that a plug can form and prevent excessive bleeding from damaged vessels. On the other hand, there is fibrinolysis, a process that keeps the blood fluid and breaks down clots. In the case of the anxiety-disorder patients, however, the researchers observed through close analysis of the blood an activation of coagulation accompanied by an inhibition of fibrinolysis. Yet, apart from the prick for blood sampling, no real injury had occurred. For these types of patients, the coagulation system goes out of balance as the coagulation tendency rises possibly with dangerous consequences. In extreme cases the imbalance can lead to blockage of a coronary artery ...
Gene therapy has freed 10 men from nearly all symptoms of hemophilia for a year so far, in a study that fuels hopes that a one-time treatment can give long-lasting help and perhaps even cure the blood...
Haemostasis (arrest of blood loss) and blood coagulation involve complex interactions between the injured vessel wall, platelets and coagulation facto
Activation of local and systemic coagulation processes are induced by several renal diseases and may require specific anticoagulation therapy. The first parts of this chapter are devoted to these...
Assay designed for the specific measurement of Factors VII-X in human citrated plasma. The assay measures Factors VII+X in human citrated plasma using a clotting method, triggered with calcium thromboplastin. Highly stable and fully reproducible assay from lot to lot.
Approximately 900,000 cases of potentially deadly blood clots, called deep vein thrombosis, are diagnosed in the United States each year, but if youre like most Americans, you might not know what a blood clot is or be aware of the symptoms. Studies show that less than one in four American adults are familiar with blood clots and can identify their signs and symptoms, and this lack of knowledge is proving to be deadly; 274 people die in the United States from blood clots each day. Although most people dont give any thought to blood clots, people who have had them know exactly how scary and serious they are. About 70 percent of blood clots are associated with known risk factors, such as surgery; these clots are considered
After a more thorough reading and research to better understand this subject, I added excerpts and package them in such a way that readers would readily undestand and find answers to their curiosity. First of all I will start by describing the role of vit K in the coagulation process. Second, I will discuss why…
Future Market Insights presents yet another comprehensive and an insightful report titled Coagulation Analysers Market: Global Industry Analysis 2012 - 2016 and Opportunity Assessment 2017 - 2027. A coagulation analyser is a type of automated analyser and is used to measure levels of blood platelets, coagulation p...
Coagulation Reagents. COAGULATION REAGENTS PRODUCT BROCHURECoagulation Reagents manufactured by High Technology, Inc. are designed for use on any open semi-automated analyzer.Innovative manufacturing technologies increase production efficiency and
Technoclone Coagulation Control Normal is a normal control plasma for use as an accuracy and precision control for coagulation analysis.
SKU: CG5023 Categories: Coagulation Controls, Quality Control Format: Lyophilised Matrix: 100% Human Material Size: 12x1ml Values: Assayed Working Stability: Stable to expiry date at 2℃ to 8℃. Reconstituted stability of up to 24 hours at 2℃ to 8℃ Available Applications: Tags: ACUSERA, Coagulation Controls, Quality Control ...
This report presents a comprehensive analysis of the German coagulation market, including:Major issues pertaining to the German coagulation laboratory
Blood clots are caused by a variety of things and can exhibit signs and symptoms depend upon the location of the clot, and may include pain, redness, and swelling in the leg; or chest pain, shortness of breath, and a rapid pulse if its in the lung. Treatment for blood clots depend upon the cause.
Blood clots are caused by a variety of things and can exhibit signs and symptoms depend upon the location of the clot, and may include pain, redness, and swelling in the leg; or chest pain, shortness of breath, and a rapid pulse if its in the lung. Treatment for blood clots depend upon the cause.
TY - JOUR. T1 - Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation. AU - Kang, Y. G.. AU - Martin, D. J.. AU - Marquez, J.. AU - Lewis, J. H.. AU - Bontempo, F. A.. AU - Shaw, B. W.. AU - Starzl, T. E.. AU - Winter, P. M.. PY - 1985/11/13. Y1 - 1985/11/13. N2 - The blood coagulation system of 66 consecutive patients undergoing consecutive liver transplantations was monitored by thrombelastograph and analytic coagulation profile. A poor preoperative coagulation state, decrease in levels of coagulation factors, progressive fibrinolysis, and whole blood clot lysis were observed during the preanhepatic and anhepatic stages of surgery. A further general decrease in coagulation factors and platelets, activation of fibrinolysis, and abrupt decrease in levels of factors V and VIII occurred before and with reperfusion of the homograft. Recovery of blood coagulability began 30-60 min after reperfusion of the graft liver, and coagulability had returned ...
2 pp. (accepted). Fibrin polymerization is a process that completes the blood coagulation cascade. Fibrin polymer forms clots. The approaches to mathematical description of blood coagulation developed up to now generally restricted by the reactions of thrombin generation. Thrombin is a key factor of blood coagulation cascade that transforms fibrinogen molecules to fibrin-monomer. The kinetics of thrombin generation depends upon a set of blood coagulation factors. Its change in time is usually described by complicated nonlinear mathematical models. In this work we made an attempt to expand thrombin generation model by the equations of fibrin polymerization. Fibrin polymerization is described by Smoluchowski equations, in correspondence with the polymerization theory [1]. Thus our model takes into account generation of fibrin-monomers, their polymerization, polymer fragmentation and degradation. The change of aggregate state of blood is a result of formation of fibrin gel. It is assumed that ...
TY - JOUR. T1 - Fibrinogen γ′ chain carboxy terminal peptide selectively inhibits the intrinsic coagulation pathway. AU - Lovely, Rehana S.. AU - Boshkov, Lynn. AU - Marzec, Ulla M.. AU - Hanson, Stephen R.. AU - Farrell, David. PY - 2007/11. Y1 - 2007/11. N2 - The minor γA/γ′ isoform of fibrinogen contains a high affinity binding site for thrombin exosite II that is lacking in the major fibrinogen isoform, γA/γA fibrinogen. The biological consequences of γ′ chain binding to thrombin were therefore investigated. Coagulation assays, thrombin activity assays, and a primate thrombosis model were used to characterize the biological effects of the γ′ 410-427 peptide. The γ′ peptide had little effect on thrombin cleavage of the small peptidyl substrate tosyl-glycyl-prolyl-arginine-4-nitranilide acetate. However, in vitro assays demonstrated that the γ′ peptide inhibited thrombin cleavage of larger proteinaceous substrates, including fibrinogen and factor VIII. The γ′ peptide ...
TY - JOUR. T1 - Contributions of procoagulants and anticoagulants to the international normalized ratio and thrombin generation assay in patients treated with warfarin. T2 - Potential role of protein Z as a powerful determinant of coagulation assays. AU - Choi, Qute. AU - Kim, Ji Eun. AU - Hyun, Jungwon. AU - Han, Kyou Sup. AU - Kim, Hyun Kyung. PY - 2013/7. Y1 - 2013/7. N2 - Background The effects of warfarin are measured with the international normalized ratio (INR). However, the thrombin generation assay (TGA) may offer more information about global coagulation. We analyzed the monitoring performance of the TGA and INR and investigated the impact of procoagulants (fibrinogen, factor (F)II, FVII, FIX, and FX) and anticoagulants (proteins C, S, and Z) on them. Methods The TGA was performed on a calibrated automated thrombogram, producing lag time, endogenous thrombin potential (ETP), and peak thrombin in 239 patients treated with warfarin. Pro- and anticoagulant levels were also measured. ...
The present study demonstrates that activation of the extrinsic coagulation pathway occurs during clinical CPB and that PBMC TF contributes to this process. TF is a cell surface transmembrane protein that, in conjunction with factor VII, causes thrombus formation through the extrinsic coagulation pathway. TF is expressed constitutively on subendothelium and organ capsules and acts as a hemostatic envelope when injury occurs to the physical barrier that normally separates factor VII from TF.14 TF usually is not present on cells in the blood or on cells that come in direct contact with blood. Specific tissues known to constitutively express TF include myocardial myocytes.13 In addition to constitutive TF expression, certain cells such as monocytes and endothelial cells can be induced to express TF in response to cytokines such as interleukin-1 and tumor necrosis factor. Cytokines are short-acting mediators of inflammation released in response to infection or tissue injury. Endotoxin (LPS), found ...
To the best of our knowledge, this is the first study investigating TG-related parameters following PCC administration in acute trauma patients. PCC therapy resulted in significantly higher ETP than in patients who received fibrinogen concentrate only or no coagulation therapy at all and, importantly, this was sustained over the first 3 to 4 days following PCC administration. AT was significantly lower in the FC-PCC group from ER admission until 3 to 4 days later, reaching a nadir on day 2. Hemostasis relies on a delicate balance between pro- and anticoagulant factors, and between thrombin potential and thrombin inhibition potential. This balance may have been impaired in the FC-PCC group, during a period when fibrinogen levels were increased above the normal range; similar findings have been reported in previous studies [34, 35]. The overall picture is increased thrombin potential (day 1 to day 4), increased substrate for coagulation (that is, fibrinogen reaching a plateau on day 4) and ...
TY - JOUR. T1 - Coagulation and fibrinolysis changes in normal pregnancy increased levels of procoagulants and reduced levels of inhibitors during pregnancy induce a hypercoagulable state, combined with a reactive fibrinolysis. AU - Cerneca, Federico. AU - Ricci, Giuseppe. AU - Simeone, Roberto. AU - Malisano, Monica. AU - Alberico, Salvatore. AU - Guaschino, Seconde. PY - 1997/5. Y1 - 1997/5. N2 - Objective: To establish the physiologic changes in the coagulation and fibrinolytic systems during normal pregnancy and puerperium. Study Design: One hundred and seventeen normal pregnant women were investigated in a longitudinal study involving five measurements: blood samples were collected at 10, 20, 30, 36 weeks and on the second day puerperium and were assayed for prothrombin time (PT expressed in INR), activated partial thromboplastin time (PLY), fibrinogen (FBG), antithrombin III activity (AT III), protein C activity (PC), protein S activity (PS), prothrombin fragments 1+2 (F1 +2), type 1 ...
The aim of this thesis is to evaluate thrombin generation in patients with thrombophilia (Paper I), in patients with venous thromboembolism (Paper II), in healthy women during the menstrual cycle (Paper III), in patients with liver disease (Paper IV) and in patients with mild deficiency of factor VII (Paper V).. For this purpose, thrombin generation was measured in platelet poor plasma by the calibrated automated thrombogram (CAT®) assay. Thrombin generation expresses the overall haemostatic potential, in contrast to the more traditional coagulation tests, which concentrate on individual factors or coagulation pathways. The thrombin generation markers that were measured and studied were: lagtime (clotting time), endogenous thrombin potential (ETP, total thrombin concentration), peak (maximum thrombin concentration) and time to peak (ttpeak).. The cohorts for Papers I and II are part of a larger cohort (The LInköping Study on Thrombosis, LIST), which included 516 consecutive patients who ...
TY - JOUR. T1 - Effects of DETANONOate, a nitric oxide donor, on hemostasis in rabbits. T2 - An in vitro and in vivo thrombelastographic analysis. AU - Nielsen, Vance G. AU - Geary, Brian T.. AU - Baird, Manuel S.. PY - 2000. Y1 - 2000. N2 - Purpose: The purpose of this study was to determine if whole blood thrombelastographic variables (reaction time, K, α, and maximum amplitude) would be adversely effected by exposure to the nitric oxide (NO) donor, DETANONOate, in vitro or after alveolar instillation in vivo. Materials and Methods: Conscious rabbits (n = 10) had blood sampled from ear arteries anticoagulated with sodium citrate. The blood was then incubated with 0, 1, 5, 10, or 20 mmol/L DETANONOate for 30 minutes. Arterial blood from anesthetized rabbits (n = 4) was obtained and anticoagulated before and 60 minutes after 1 mmol/L DETANONOate (2 mL/kg) was instilled into the right lung. After incubation, all samples were placed in a thrombelastograph and recalcified, with thrombelastographic ...
Abstract:. Objective: To investigate the blood coagulation function in COVID-19 patients, and the correlation between coagulopathy and disease severity. Methods: We retrospectively collected 147 clinically diagnosed COVID-19 patients at Wuhan Leishenshan Hospital of Hubei, China. We analyzed the coagulation function in COVID-19 patients through the data including thrombin-antithrombin complex (TAT), 2-plasmininhibitor-plasmin Complex (PIC), thrombomodulin (TM), t-PA/PAI-1 Complex (t-PAIC), prothrombin time (PT), international normalized ratio (INR), activated partial thromboplastin time (APTT), fibrinogen (FIB), thrombin time (TT), D-Dimer (DD), and platelet (PLT). Result: The levels of TAT, PIC, TM, t-PAIC, PT, INR, FIB, and DD in COVID-19 patients were higher than health controls ( ...
TY - JOUR. T1 - The coagulation system, but not circulating fibrinogen, contributes to liver injury in rats exposed to lipopolysaccharide from gram-negative bacteria. AU - Hewett, J. A.. AU - Roth, R. A.. PY - 1995. Y1 - 1995. N2 - Evidence suggests that components of the coagulation system contribute to the pathogenesis of liver injury after exposure to lipopolysaccharide (LPS) from gram-negative bacteria. Although the mechanism by which the coagulation system mediates liver injury remains unknown, it has been proposed that the conversion of fibrinogen to insoluble fibrin and consequent deposition in liver microvasculature may contribute to the development of liver injury. The purpose of this study was to test the hypothesis that the coagulation system contributes to LPS hepatotoxicity by a mechanism which is dependent on circulating fibrinogen. A marked reduction in plasma fibrinogen concentration occurred in rats after LPS exposure. The decrease in circulating fibrinogen, which marked ...
TY - JOUR. T1 - Effect of graded exercise on platelet count, adhesion and aggregation. AU - Arao, T.. AU - Ikuyama, T.. AU - Osanai, H.. PY - 1979. Y1 - 1979. N2 - It is generally accepted that platelet is one of the important factors in blood coagulability, and many studies have reported that short strenuous exercise would increase platelet count and function. However, we have been unable to find any studies on such changes during the course of graded exercise. In the present study, therefore, we investigated the changes in platelet count and function during three different graded exercise on a bicycle ergometer.. AB - It is generally accepted that platelet is one of the important factors in blood coagulability, and many studies have reported that short strenuous exercise would increase platelet count and function. However, we have been unable to find any studies on such changes during the course of graded exercise. In the present study, therefore, we investigated the changes in platelet count ...
Cablivi is the first therapeutic approved in Europe, for the treatment of a rare blood-clotting disorder On September 03, 2018, the European Commission has granted marketing authorization for Cablivi™ (caplacizumab) for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), a rare blood-clotting disorder. Cablivi is the first therapeutic specifically indicated…
TY - JOUR. T1 - Evidence for factor IX-independent roles for factor XIa in blood coagulation. AU - Matafonov, A.. AU - Cheng, Q.. AU - Geng, Y.. AU - Verhamme, I. M.. AU - Umunakwe, O.. AU - Tucker, E. I.. AU - Sun, M. F.. AU - Serebrov, Vladimir Yurievich. AU - Gruber, A.. AU - Gailani, D.. PY - 2013/12. Y1 - 2013/12. N2 - Summary: Background: Factor XIa is traditionally assigned a role in FIX activation during coagulation. However, recent evidence suggests this protease may have additional plasma substrates. Objective: To determine whether FXIa promotes thrombin generation and coagulation in plasma in the absence of FIX, and to determine whether FXI-deficiency produces an antithrombotic effect in mice independently of FIX. Methods: FXIa, FXIa variants and anti-FXIa antibodies were tested for their effects on plasma coagulation and thrombin generation in the absence of FIX, and for their effects on the activation of purified coagulation factors. Mice with combined FIX and FXI deficiency were ...
Thromboelastography (TEG) is a method of testing the efficiency of blood coagulation. It is a test mainly used in surgery and anesthesiology, although few centers are capable of performing it. More common tests of blood coagulation include prothrombin time (PT,INR) and partial thromboplastin time (aPTT) which measure coagulation factor function, but TEG also can assess platelet function, clot strength, and fibrinolysis which these other tests cannot. Thromboelastometry (TEM), previously named rotational thromboelastography (ROTEG) or rotational thromboelastometry (ROTEM), is another version of TEG in which it is the sensor shaft, rather than the cup, that rotates. A small sample of blood is taken from the selected person and rotated gently through 4º 45, six times a minute, to imitate sluggish venous flow and activate coagulation. A thin wire probe is used to measure, which the clot forms around. The speed and strength of clot formation is measured in various ways, typically by computer. The ...
Abstract. Human antithrombin III (ATIII) is a plasma inhibitor of several serine proteases of the blood coagulation system. Previous investigations have report
5-R-Rivaroxaban is a selective inhibitor of human Factor Xa with IC50 value of 0.7 nmol/L. Factor Xa is a serine endopeptidase enzyme and plays an important role in the convergence point of the intrinsic and extrinsic pathways in blood coagulation system. 5-R-Rivaroxaban is an oral, direct factor Xa inhibitor and the inhibition is species-dependent. When tested with purified factoe Xa from human or rabbit, 5-R-Rivaroxaban showed similar affinity with IC50 value of 0.7 nmol/L and 0.8 nmol/L, respectively, while had a IC50 value as low as 3.4 nmol/L when tested with rat factor Xa. Pre-treated anaesthetised rat model with intravenous 5-R-Rivaroxaban at a dose of 2 mg/kg, and after bleeding initiated intravenous treated with rFVIIa (100/400 μg/kg), PCC (25/50 U/kg) or aPCC (50/100 U/kg), the result showed that 5-R-Rivaroxaban pre-treatment significantly shorten bleeding time and clotting time compared with 5-R-Rivaroxaban alone treated group. Similar results were obtained when tested with rabbit ...
There is limited knowledge of whether hypercoagulability is present after subarachnoid hemorrhage (SAH) or about its timing of onset, duration, and severity. To conduct a pilot new generation thromboelastography (TEG) technology (TEG6s) -based and conventional coagulation test-supported longitudinal assessment of coagulation in patients with SAH. We prospectively enrolled non-traumatic SAH patients on admission from May 2015 to May 2016. We performed TEG6s measurements and conventional coagulation tests on days 1, 2, 3, 5, 7, 10 and 14 and compared them to TEG6s parameters in healthy volunteers. We studied 14 patients and 72 TEG6s measurements. Of these patients, 10 (71.4%) were admitted to ICU. Mean age was 57.5 (±14.5), APACHE III score 58.2(±26.6), length of hospital stay of 23 (±11.7) days and mortality was 14.3%. At baseline, conventional coagulation tests were within normal range. However, TEG6s parameters already showed increased coagulability. Thereafter, alpha angle, reaction time, ...
We use cookies to ensure that we give you the best experience on our website. If you click Continue well assume that you are happy to receive all cookies and you wont see this message again. Click Find out more for information on how to change your cookie settings ...
Coronary artery bypass grafting with extracorporal circulation is established as the golden standard. The conventional cardiopulmonary bypass (CPB) system is associated with inflammatory reaction, hemolysis, hemodilution an disturbances of the blood coagulation system. Also its well known that neurological disturbances caused by embolic material and air bubbles are potential risks of CPB. The new minimized perfusion circuit ROCsafeTM is a closed, reservoir-less, reduced prime, surface coated circuit, with optimized safety features in effectively eliminate both macro and micro air bubbles and should optimize the clinical outcome after CABG using cardiopulmonary bypass. ...
Thromboelastography (TEG) is a point-of-care whole blood coagulation monitor which provides information on specific aspects of coagulation including time to production of initial fibrin strands (R-time), time to develop clot (R-time, K-time), rate of fibrin build-up and cross linking (-angle), maximum clot strength (maximum amplitude bMA) and measures of fibrinolysis (decreasing amplitude post-MA). Abnormal TEG data may predict patients who will bleed. Spiess [2] found that TEG correlated well with ACT and coagulation profiles and whilst no coagulation test was consistently abnormal the TEG was the most accurate predictor of bleeding. Ereth studied a Platelet-activated clotting test (PACT HemoSTATUS), ACT and clotting studies, and TEG. Whilst PACT sensitivity and specificity was comparable to conventional coagulation tests in predicting blood loss, TEG was more predictive at both blood loss levels. Essell found that whilst the bleeding time and platelet count had sensitivities similar to the ...
1JC9: The 2.0-A crystal structure of tachylectin 5A provides evidence for the common origin of the innate immunity and the blood coagulation systems.
OBJECTIVES: Exercise induces changes in haemostatic parameters and core body temperature (CBT). We aimed to assess whether exercise-induced elevations in CBT induce pro-thrombotic changes in a dose-dependent manner. DESIGN: Observational study. METHODS: CBT and haemostatic responses were measured in 62 participants of a 15-km road race at baseline and immediately after finishing. As haemostasis assays are routinely performed at 37°C, we corrected the assay temperature for the individuals actual CBT at baseline and finish in a subgroup of n=25. RESULTS: All subjects (44±11 years, 69% male) completed the race at a speed of 12.1±1.8km/h. CBT increased significantly from 37.6±0.4°C to 39.4±0.8°C (p,0.001). Post-exercise, haemostatic activity was increased, as expressed by accelerated thrombin generation and an attenuated plasmin response. Synchronizing assay temperature to the subjects actual CBT resulted in additional differences and stronger acceleration of thrombin generation parameters. ...
It is not known whether the mammalian mechanism of coagulation initiation is conserved in fish. Identification of factor VII is critical in providing evidence for such a mechanism. A cDNA was cloned from a zebrafish (teleost) library that predicted a protein with sequence similarity to human factor VII. Factor VII was shown to be present in zebrafish blood and liver by Western blot analysis and immunohistochemistry. Immunodepletion of factor VII from zebrafish plasma selectively inhibited thromboplastin-triggered thrombin generation. Heterologous expression of zebrafish factor VII demonstrated a secreted protein (50 kDa) that reconstituted thromboplastin-triggered thrombin generation in immunodepleted zebrafish plasma. These results suggest conservation of the extrinsic coagulation pathway between zebrafish and humans and add credence to the zebrafish as a model for mammalian hemostasis. The structure of zebrafish factor VIIa predicted by homology modeling was consistent with the overall ...
It is not known whether the mammalian mechanism of coagulation initiation is conserved in fish. Identification of factor VII is critical in providing evidence for such a mechanism. A cDNA was cloned from a zebrafish (teleost) library that predicted a protein with sequence similarity to human factor VII. Factor VII was shown to be present in zebrafish blood and liver by Western blot analysis and immunohistochemistry. Immunodepletion of factor VII from zebrafish plasma selectively inhibited thromboplastin-triggered thrombin generation. Heterologous expression of zebrafish factor VII demonstrated a secreted protein (50 kDa) that reconstituted thromboplastin-triggered thrombin generation in immunodepleted zebrafish plasma. These results suggest conservation of the extrinsic coagulation pathway between zebrafish and humans and add credence to the zebrafish as a model for mammalian hemostasis. The structure of zebrafish factor VIIa predicted by homology modeling was consistent with the overall ...
The use of mouse models for the study of thrombotic disorders has gained increasing importance. Methods for measurement of coagulation activation in mice are, however, scarce. The primary aim of this study was to develop a specific mouse thrombin-antithrombin (TAT) ELISA for measurement of coagulation activation and to compare it with two commercially available assays for human TAT complexes. In addition, we aimed to improve methods for mouse plasma anticoagulation and preparation. First, for the measurement of TAT-complexes in plasma a mouse specific TAT-ELISA was developed using rabbit polyclonal antibodies raised against mouse thrombin and rat antithrombin, respectively. This ELISA detected an increase in TAT levels in a mouse model of endotoxemia. Two commercial human TAT ELISAs appeared to be less specific for mouse thrombin-rat antithrombin complexes. Second, to prevent clotting of mouse blood sodium citrate was either mixed with blood during collection in a syringe or was injected intravenously
OBJECTIVES: Exercise induces changes in haemostatic parameters and core body temperature (CBT). We aimed to assess whether exercise-induced elevations in CBT induce pro-thrombotic changes in a dose-dependent manner. DESIGN: Observational study. METHODS: CBT and haemostatic responses were measured in 62 participants of a 15-km road race at baseline and immediately after finishing. As haemostasis assays are routinely performed at 37 degrees C, we corrected the assay temperature for the individuals actual CBT at baseline and finish in a subgroup of n=25. RESULTS: All subjects (44+/-11 years, 69% male) completed the race at a speed of 12.1+/-1.8km/h. CBT increased significantly from 37.6+/-0.4 degrees C to 39.4+/-0.8 degrees C (p,0.001). Post-exercise, haemostatic activity was increased, as expressed by accelerated thrombin generation and an attenuated plasmin response. Synchronizing assay temperature to the subjects actual CBT resulted in additional differences and stronger acceleration of ...
Formulation of a medical preparedness plan for treating severely bleeding casualties during naval deployment is a significant challenge because of territory covered during most missions. The aim of this study was to evaluate the concept of walking blood bank as a supportable plan for supplying safe blood and blood products. In 2013, the Royal Norwegian Navy conducted antipiracy operations from a frigate, beginning in the Gulf of Aden and ending in the Indian Ocean. Crews were on 24-hour emergency alert in preparation for an enemy assault on the frigate. Under an approved command protocol, a walking blood bank, using crew blood donations, was established for use on board and on missions conducted in rigid-hulled inflatable boats, during which freeze-dried plasma and leukoreduced, group O low anti-A anti-B titer, cold-stored whole blood were stored in Golden Hour Boxes. Data demonstrating the ability to collect, store, and provide whole blood were collected to establish feasibility of implementing a whole
2018 Elsevier Inc. All rights reserved. Transfusion medicine physicians and laboratory scientists are confronted daily with hemostasis and thrombosis-related concerns as they select and administer blood components, coagulation factor concentrates, anticoagulants, and agents to manage anticoagulant therapy. This chapter provides an introduction and overview of hemostasis. Primary hemostasis focuses on platelet function and interactions with the vasculature, endothelium, and the coagulation mechanism. Secondary hemostasis focuses on the coagulation cascade and is subdivided into the extrinsic, intrinsic, and common enzymatic pathways. Coagulation also includes control systems such as protein C, protein S, and antithrombin, and fibrinolysis. Depending on the defect, hemostasis disorders may be congenital or acquired, resulting in hemorrhage or thrombosis. The questions in this chapter will explore normal hemostasis, disorders of hemostasis, and the laboratory assays that predict, identify, and ...
Principal Investigator:MATSUI Yoshihiko, Project Period (FY):2002 - 2004, Research Category:Grant-in-Aid for Scientific Research (B), Section:一般, Research Field:Civil and environmental engineering
TY - JOUR. T1 - Structure of Ca+2 -free Gla diomain shed light on membrane binding of blood coagulation proteins. AU - Sunnerhagen, Maria. AU - Forsen, Sture. AU - Hoffren, Anna-Marja. AU - Drakenberg, Torbjörn. AU - Teleman, Olle. AU - Stenflo, Johan. N1 - Project code: B5SU00139. PY - 1995. Y1 - 1995. N2 - Reversible membrane binding of γ-carboxyglutamic acid (Gla)-containing coagulation factors requires Ca2+-binding to 10-12 Gla residues. Here we describe the solution structure of the Ca2+-free Gla-EGF domain pair of factor X which reveals a striking difference between the Ca2+-free and Ca2+-loaded forms. In the Ca2+-free form Gla residues are exposed to solvent and Phe 4, Leu 5 and Val 8 form a hydrophobic cluster in the interior of the domain. In the Ca2+-loaded form Gla residues ligate Ca22+ in the core of the domain pushing the side-chains of the three hydrophobic residues into the solvent. We propose that the Ca2+-induced exposure of hydrophobic side chains is crucial for membrane ...
Abnormal Blood Coagulation Studies (Prolonged PT and PTT) Symptom Checker: Possible causes include Vitamin K Deficiency. Check the full list of possible causes and conditions now! Talk to our Chatbot to narrow down your search.
By Makia Freeman Doctor Exposes the Corona Effect - COVID is Blood Coagulation Thursday, July 16, 2020 Is COVID not actually a viral condition but due to blood coagulation and the corona effect caused by acidosis? The Corona Effect In relation to viruses is a phrase used by naturopathic practitioner Dr. Robert Youn
A prothrombotic state is one of the hallmarks of advanced cancer, and thromboembolic disease contributes significantly to the mortality of cancer patients (reviewed in1). Tissue factor (TF), the cellular activator of the coagulation cascade, is central to the hypercoagulable state of cancer patients and responsible for local thrombin generation and fibrin deposition in the tumor stroma. TF also triggers remote thrombotic complications involving procoagulant TF+ microparticles2 with potential contribution from other cancer procoagulants (reviewed in3). TF-dependent coagulation generates thrombin and induces pleiotrophic cellular effects of thrombin on platelets through G protein-coupled protease-activated receptors (PARs)4 as well as thrombin-initiated vascular-protective signaling of the endogenous activated protein C-EPCR-PAR1 pathway.5 Direct signaling by TF-associated proteases are mediated by the binary TF-VIIa enzyme complex that activates PAR2 or the ternary TF-VIIa-Xa coagulation ...
...ATLANTA Oct. 25 /- CryoLife Inc. (NYSE: a href ... PerClot is an exciting technology platform that has seen success in E...The European hemostatic market is estimated to be $279 million in 2010...On September 28 2010 CryoLife entered into a worldwide distribution ...,CryoLife,Begins,Distribution,of,Blood-Clotting,Agent,PerClot®,in,Europe,medicine,advanced medical technology,medical laboratory technology,medical device technology,latest medical technology,Health
Inhalation of fine particulate matter (< 2.5 mu m; fine PM) has been shown to increase the risk for cardiovascular events. In this letter, we reappraise the role of tissue factor (TF) antigen and we also summarize changes in measured coagulation proteins in humans and rodents by other studies with fine PM. By considering all studies including ours, we conclude that monitoring the overall coagulation state by measuring capacity assays such as thrombin generation, and quantification of TF activity would be more suitable than determining single coagulation proteins (such as TF antigen) in order to better assess the systemic prothrombotic effects of fine PM. ...
Bambakidis, T., Dekker, S. E., Halaweish, I., Liu, B., Nikolian, V. C., Georgoff, P. E., Piascik, P., Li, Y., Sillesen, M. & Alam, H. B., sep. 2017, I: Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 28, 6, s. 479-484 6 s.. Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review ...
1] A new two-dimensional aerosol bin scheme, which resolves both aerosol size and black carbon (BC) mixing state for BC aging processes (e.g., condensation and coagulation) with 12 size × 10 mixing state bins, has been developed and implemented into the WRF-chem model (MS-resolved WRF-chem). The mixing state of BC simulated by this model is compared with direct measurements over the East Asian region in spring 2009. Model simulations generally reproduce the observed features of the BC mixing state, such as the size-dependent number fractions of BC-containing and BC-free particles and the coating thickness of BC-containing particles. This result shows that the model can simulate realistic BC mixing states in the atmosphere if condensation and coagulation processes are calculated explicitly with the detailed treatment of BC mixing state. Sensitivity simulations show that the condensation process is dominant for the growth of thinly coated BC particles, while the coagulation process is necessary ...
The present article aims to provide clinicians with an overview of coagulation testing in individuals with liver disease, to discuss available procoagulants and the rationale for their use, and to provide management strategies in a variety of common clinical scenarios.Clinicians and researchers are gaining an increased understanding of the shortfalls of assessing bleeding risk using traditional tests of coagulation. The use of global tests of clot formation, including viscoelastic testing and thrombin generation analysis, continues to evolve and guide the management of these patients.Abnormal coagulation testing in individuals with cirrhosis leads to a variety of difficult clinical scenarios that can be challenging for practitioners. With advanced liver disease, changes in the traditional tests of hemostasis such as the international normalized ratio reflect decreased synthesis of procoagulant factors but do not capture concomitant decreases in anticoagulant factors. In this setting, transfusion ...
The liver synthesizes the majority of pro- and anti-coagulant and fibrinolytic proteins, and during liver dysfunction synthesis of these proteins is reduced. The end point of conventional hemostatic tests, such as the prothrombin time (PT), occurs when only 5% of thrombin generation (TG) has taken place and is not sensitive to the effects of natural anti-coagulants. The aim of this study was to determine whether TG in the presence of thrombomodulin (TM) provides more useful information about coagulation potential, in comparison to the PT. Analysis was performed on ST Genesia, a novel TG analyzer from Diagnostica Stago. TG was measured using STG-Thromboscreen, a reagent containing an intermediate concentration of human tissue factor (TF) ± rabbit TM to account for anti-coagulant protein C (PC) activity. Platelet-poor plasma (PPP) samples were from the Intensive Care Study of Coagulopathy-2 (ISOC-2), which recruited patients admitted to critical care with a prolonged PT (3 seconds above the reference
Pneumonia Blood Clots In Lungs blood clot in lung survival rate, blood clots causes, blood clots in lungs serious, blood clots in lungs symptoms, multiple blood clots in lungs, natural treatment for blood clots in the lungs, treatment for blood clot in lung when pregnant, treatment for blood clot in lung while pregnant, what is a lung embolism
Rising awareness about timely diagnosis of blot clots to add growth impetus to coagulation analyzers market Market Size - USD 5.1 billion in 2020 Market Growth - 10.6% Market Trends - Increasing disposition towards blood clots.. The global Coagulation Analyzers Market size is expected to reach USD 11.7 billion by 2028 at a CAGR of 10.6%, according to a new report by Reports and Data.. As well as vitamin K deficiency and heart disease, genetic disorders can contribute to blood clotting. The increasing understanding of blood clots and the fact that they can be avoided with early detection are factors driving the demand for coagulation analyzers. More than 100,000 individuals die per year in the U.S. due to blood clots, according to the CDC. Without warning, people with pulmonary embolism sometimes die. These variables are also driving the growth of the market for coagulation analyzers.. Over the coming years, lack of knowledge of timely blood clot detection and lack of qualified coagulation ...
Oxidized cholesterol compounds or oxysterols are thought to be potent membrane-destabilizing agents. Anionic phospholipids, chiefly phosphatidylserine, have a procoagulant potential due to their ability to favour the membrane assembly of the characteristic clotting enzyme complexes including the tissue factor-dependent initiating complex. However, in resting cells, phosphatidylserine is sequestered in the inner leaflet of the plasma membrane. When THP-1 monocytic cells were cultured in the presence of 7β-hydroxycholesterol (7β-OH) or 25-hydroxycholesterol (25-OH), prothrombinase, which reflects anionic phospholipid exposure and tissue factor (TF) procoagulant activities, increased in a time- and dose-dependent manner. 7β-OH appeared 1.5- to 2-fold more potent than 25-OH. Interestingly, no effect of cholesterol itself could be detected on procoagulant activities. Nevertheless, no difference in TF activity could be detected between oxysterol-treated and control cells after disruption. TF ...
Blood coagulation experiments. Sigmund Rascher experimented with the effects of Polygal, a substance made from beet and apple ... This caused the blood cells to congeal, and the blood was studied. When the Nazis removed blood from someone, they often ... blood coagulation and phlegmon.[2] According to the indictments at the Subsequent Nuremberg Trials,[3][4] these experiments ... Circulation of blood was interrupted by tying off blood vessels at both ends of the wound to create a condition similar to that ...
Blood coagulation experiments[edit]. Rascher experimented with the effects of Polygal, a substance made from beet and apple ... He conducted deadly experiments on humans about high altitude, freezing and blood coagulation under SS leader Heinrich Himmler' ... pectin, which aided blood clotting. He predicted that the preventive use of Polygal tablets would reduce bleeding from gunshot ...
Blood coagulation factors[edit]. *Coagulation factor VIIIα. *Coagulation factor IXα ... Blood products of human origin and plasma substitutes[edit]. Blood and blood components[edit]. ... 11 Blood products of human origin and plasma substitutes *11.1 Blood and blood components ...
Type II domains have also been found in a range of proteins including blood coagulation factor XII; bovine seminal plasma ... Fibronectins are involved in a number of important functions e.g., wound healing; cell adhesion; blood coagulation; cell ... Structural similarity of the protease precursor to blood coagulation factor XII". J. Biol. Chem. 268 (14): 10024-10028. PMID ...
... which plays a key role in causing blood to clot (blood coagulation). G20210A can thus contribute to a state of ... "Blood. 88 (10): 3698-703. PMID 8916933.. *^ Ye Z, Liu EH, Higgins JP, Keavney BD, Lowe GD, Collins R, et al. (2006). "Seven ... Occasionally, blood-thinning medication may be indicated to reduce the risk of clotting.[10][better source needed] ... Deficiencies in the anticoagulants Protein C and Protein S further increase the risk five- to tenfold.[2] Behind non-O blood ...
Blood Coagulation & Fibrinolysis. 23 (1): 45-50. doi:10.1097/mbc.0b013e32834d7ce3. PMID 22024796. S2CID 3327902. Keane C, ... Blood. 90 (3): 1109-14. doi:10.1182/blood.V90.3.1109. PMID 9242542. Nourse JP, Lea R, Crooks P, Wright G, Tran H, Catalano J, ...
8 (5). de Boer JD, Majoor CJ, van 't Veer C, Bel EH, van der Poll T (April 2012). "Asthma and coagulation". Blood. 119 (14): ... doi:10.1182/blood-2011-11-391532. PMID 22262775. Middleton's Allergy Principles & Practice, N. F. Adkinson, B. S. Bochner, W. W ...
Budzynski, A. Z. (February 1991). "Interaction of hementin with fibrinogen and fibrin". Blood Coagulation & Fibrinolysis. 2 (1 ... which the Amazon leech inserts into the host to suck the blood. Hementin dissolves platelet-rich blood clots and lets the blood ... Blood Coagulation & Fibrinolysis. DOI: 10.1097/00001721-199102000-00023 (1): 153-9. doi:10.1097/00001721-199102000-00023. PMID ... The processes of blood anticoagulation by hementin includes the degradation of fibrinogen. It is capable of disrupting the ...
Blood Coagulation & Fibrinolysis. 16 (1): 1-7. doi:10.1097/00001721-200501000-00001. PMID 15650539. S2CID 44664652. Melzer C, ... It binds to the fibrin component of the thrombus (blood clot) and selectively converts thrombus-bound plasminogen to plasmin, ...
Blood Coagulation & Fibrinolysis. 19 (7): 709-718. doi:10.1097/MBC.0b013e32830b2891. PMC 2713681. PMID 18832915. "Genomatix: ...
Blood Coagulation & Fibrinolysis. 19 (7): 709-18. doi:10.1097/MBC.0b013e32830b2891. PMC 2713681. PMID 18832915. Lee, J; Zheng, ... for DX-2400, a Matrix metalloproteinase-14 (MPP-14) targeted monoclonal antibody intended to inhibit tumor blood vessel ...
Franco, David; Everett, George; Manoucheri, Manoucher (2013). "I smell a rat". Blood Coagulation & Fibrinolysis. 24 (2): 202-4 ... the blood plasma and blood itself begin to leak from the smallest blood vessels. A poisoned animal suffers progressively ... Blood, 76 (12): 2555-2559, doi:10.1182/blood.V76.12.2555.2555 "COCA Clinical Action: Outbreak Alert Update: Potential Life- ... A complete blood count and complete metabolic panel were normal. Prothrombin time (PT) was above 100 s, partial thromboplastin ...
Marsh, NA (July 1998). "Use of snake venom fractions in the coagulation laboratory". Blood Coagulation & Fibrinolysis. 9 (5): ... Blood Coagulation & Fibrinolysis. 1 (3): 259-66. doi:10.1097/00001721-199008000-00002. PMID 2129412. Laboratory testing for the ... Blood. 68 (4): 869-74. doi:10.1182/blood.V68.4.869.869. PMID 3092888. Exner, T; Papadopoulos, G; Koutts, J (August 1990). "Use ... Exner, T; Rickard, KA; Kronenberg, H (October 1975). "Studies on phospholipids in the action of a lupus coagulation inhibitor ...
Coagulation, the formation of a blood clot or thrombus, occurs when the proteins of the coagulation cascade are activated, ... In addition, it is used in the diagnosis of the blood disorder disseminated intravascular coagulation. A four-fold increase in ... D-dimers are not normally present in human blood plasma, except when the coagulation system has been activated, for instance ... D-dimer (or D dimer) is a fibrin degradation product (or FDP), a small protein fragment present in the blood after a blood clot ...
... inhibiting several blood coagulation enzymes counting thrombin and factor Xa. In the beginning, protein C inhibitor(PCI) was ... Blood Coagulation & Fibrinolysis. 4 (6): 921-6. doi:10.1097/00001721-199304060-00009. PMID 8148485. Hayashi T, Suzuki K ( ... Blood Coagulation & Fibrinolysis. 4 (1): 153-8. doi:10.1097/00001721-199304010-00027. PMID 8384496. Moore A, Penfold LM, ... Blood Coagulation & Fibrinolysis. 6 (5): 382-7. doi:10.1097/00001721-199507000-00003. PMID 8589203. The MEROPS online database ...
... s, commonly known as blood thinners, are chemical substances that prevent or reduce coagulation of blood, ... Citrate is in liquid form in the tube and is used for coagulation tests, as well as in blood transfusion bags. It binds the ... A Bethesda unit (BU) is a measure of blood coagulation inhibitor activity. It is the amount of inhibitor that will inactivate ... Apixaban had no effect on mortality, recurrence of blood clots in blood vessels or major bleeding or minor bleeding, however ...
Blood Coagulation & Fibrinolysis. 25 (5): 507-511. doi:10.1097/MBC.0000000000000057. ISSN 1473-5733. PMID 24553060. Gardella, ... Blood Coagulation & Fibrinolysis. 25 (5): 507-511. doi:10.1097/MBC.0000000000000057. ISSN 1473-5733. PMID 24553060. Gardella, ... Blood Coagulation & Fibrinolysis. 25 (5): 507-511. doi:10.1097/MBC.0000000000000057. ISSN 1473-5733. PMID 24553060. Chinsakchai ... It is characterized by progressive lower extremity edema distal to the thigh, tight shiny skin, cyanosis (inadequate blood ...
Blood Coagulation & Fibrinolysis. 19 (7): 709-18. doi:10.1097/MBC.0b013e32830b2891. PMC 2713681. PMID 18832915. Park J, Chun KH ... Blood. 127 (17): 2144-54. doi:10.1182/blood-2015-10-678706. PMC 4850869. PMID 26983850. Shanley M (October 6, 2017). "Therapy ...
... participates in blood coagulation; it is a cofactor for factor IXa which, in the presence of Ca2+ and phospholipids ... Villoutreix BO, Dahlbäck B (June 1998). "Structural investigation of the A domains of human blood coagulation factor V by ... "NIH: F8 - coagulation factor VIII". National Institutes of Health. "Entrez Gene: F8 coagulation factor VIII, procoagulant ... The active protein (sometimes written as coagulation factor VIIIa) interacts with another coagulation factor called factor IX. ...
Blood Coagulation and Fibrinolysis. 12 (2): 123-8. doi:10.1097/00001721-200103000-00006. PMID 11302474. S2CID 28411589. ...
Blood Coagulation and Fibrinolysis. 22(2): 110-7 (2011). Ignjatovic V, Straka E, Summerhayes R, Monagle P. Age-specific ... The haemostatic (blood clotting) system involves the interaction of proteins in the blood, the blood vessel wall and the flow ... They form aggregates with white blood cells and in adults the platelets that are bound to white blood cells are usually ... There is more Antithrombin bound to Heparin in blood from newborns compared to blood from adults, suggesting different ...
Blood Coagulation and Fibrinolysis. 12 (2): 123-8. doi:10.1097/00001721-200103000-00006. PMID 11302474. Mlinarič, A.; Kreft, S ...
Blood Coagulation and Fibrinolysis. 12 (2): 123-8. doi:10.1097/00001721-200103000-00006. PMID 11302474. S2CID 28411589. ... and impaired coagulation. No definitive antidote for amatoxin poisoning is available, but some specific treatments have been ...
"Statins and Blood Coagulation". doi:10.1161/ Cite journal requires ,journal= (help). ... In coagulation, the procoagulant protein factor X can be activated into factor Xa two ways; extrinsically or intrinsically. The ...
Blood Coagulation and Fibrinolysis. 12 (2): 123-8. doi:10.1097/00001721-200103000-00006. PMID 11302474. S2CID 28411589. Media ...
Blood Coagulation and Fibrinolysis. 19 (2): 109-119. doi:10.1097/mbc.0b013e3282f41e3e. PMID 18277131. Kahr, 2001 McKay & Haq, ... Blood. 87 (12): 4967-78. doi:10.1182/blood.V87.12.4967.bloodjournal87124967. PMID 8652809. Diamandis M, Veljkovic DK, Maurer- ... Blood. 115 (6): 1264-6. doi:10.1182/blood-2009-07-233965. PMID 20007542. Blavignac, Jessica; Bunimov, Natalia; Rivard, Georges ... The mutation causes overproduction of uPA, an enzyme that accelerates blood clot breakdown. Genetic testing is the only way to ...
"Blood-coagulation factor XIII". Drug Information Portal. U.S. National Library of Medicine. Medicine portal v t e. ... J Blood Med. 5: 107-13. doi:10.2147/JBM.S35395. PMC 4096448. PMID 25031548. Mozaffari S, Nikfar S, Abdollahi M (July 2015). " ... First drug to treat rare genetic blood clotting disorder. The Pharmacist February 01, 2014 Korte W (9 July 2014). "Catridecacog ...
Blood Coagulation and Fibrinolysis. 12 (2): 123-8. doi:10.1097/00001721-200103000-00006. PMID 11302474. S2CID 28411589. E. ...
"Blood-coagulation factor VIII, procoagulant". Drug Information Portal. U.S. National Library of Medicine. "Beroctocog alfa". ... Proceedings of the Twelfth Annual Symposium on Blood Transfusion, Groningen 1987, organized by the Red Cross Blood Bank ... This transfer of a plasma byproduct into the blood stream of a hemophiliac often led to the transmission of diseases such as ... A purified factor VIII concentrate is made from human blood plasma. A recombinant version is also available. People may develop ...
"Expression of human blood coagulation factor XI: characterization of the defect in factor XI type III deficiency". Blood. 79 (6 ... Fujikawa K, Chung DW, Hendrickson LE, Davie EW (May 1986). "Amino acid sequence of human factor XI, a blood coagulation factor ... Fujikawa K, Chung DW, Hendrickson LE, Davie EW (May 1986). "Amino acid sequence of human factor XI, a blood coagulation factor ... Walsh PN (Jul 2001). "Roles of platelets and factor XI in the initiation of blood coagulation by thrombin". Thrombosis and ...
... and abnormalities in blood clotting often consistent with disseminated intravascular coagulation (DIC) such as a prolonged ... This may cause vomiting blood, coughing up of blood, or blood in stool.[32] Bleeding into the skin may create petechiae, ... Blood products such as packed red blood cells, platelets, or fresh frozen plasma may also be used.[135] Other regulators of ... an initially decreased white blood cell count followed by an increased white blood cell count; elevated levels of the liver ...
... ductus arteriosus blood vessel.[47][150] Prolonged use of salicylic acid over significant areas of the skin or under occlusive ...
Pages in category "Blood proteins". The following 39 pages are in this category, out of 39 total. This list may not reflect ... Retrieved from "" ...
Cord blood has a higher concentration of HSC than is normally found in adult blood. However, the small quantity of blood ... Coagulation issues and inflammation of atherosclerotic plaques are known to occur as a result of G-CSF injection. G-CSF has ... Umbilical cord blood[edit]. Umbilical cord blood is obtained when a mother donates her infant's umbilical cord and placenta ... Allogeneic cord blood is stored frozen at a cord blood bank because it is only obtainable at the time of childbirth. To ...
positive regulation of coagulation. • negative regulation of apoptotic signaling pathway. • neuron development. • memory. • ... blood vessel development. • membrane protein ectodomain proteolysis. • regulation of epidermal growth factor-activated receptor ...
McMullen BA, Fujikawa K, Kisiel W, et al. (1983). „Complete amino acid sequence of the light chain of human blood coagulation ... Hassan HJ, Leonardi A, Chelucci C, et al. (1990). „Blood coagulation factors in human embryonic-fetal development: preferential ... Leytus SP, Foster DC, Kurachi K, Davie EW (1986). „Gene for human factor X: a blood coagulation factor whose gene organization ... Fung MR, Hay CW, MacGillivray RT (1985). „Characterization of an almost full-length cDNA coding for human blood coagulation ...
t-PA is released into the blood very slowly by the damaged endothelium of the blood vessels, such that, after several days ( ... Coagulation inhibitors. *Antithrombin (inhibits II, IX, X, XI, XII). *Protein C (inhibits V, VIII)/Protein S (cofactor for ... In fibrinolysis, a fibrin clot, the product of coagulation, is broken down.[2] Its main enzyme plasmin cuts the fibrin mesh at ... Fibrinolysis is a process that prevents blood clots from growing and becoming problematic.[1] This process has two types: ...
It is the blood plasma without the fibrinogens. Serum includes all proteins not used in blood clotting (coagulation) and all ... Anti-coagulated blood yields plasma containing fibrinogen and clotting factors. Coagulated blood (clotted blood) yields serum ... Serum is a clear, yellowish coloured fluid which is part of the blood.[1] It does not contain white or red blood cells or a ... "blood serum or serum". Collins Dictionary of Biology. 2005. Retrieved 16 June 2012.. ...
... tumours that block or hoard blood supply, and disseminated intravascular coagulation or other thromboses. ... This is due to the lysis of neutrophils, a type of white blood cell, caused by the lecithinases and other toxins released by ... compare to 4-5 kPa in venous blood under normal conditions, with 11-13 kPa in arteries and 21 kPa in air at sea level), so if ...
APS provokes blood clots (thrombosis) in both arteries and veins as well as pregnancy-related complications such as miscarriage ... Thus, anti-annexin A5 antibodies increase phospholipid-dependent coagulation steps.[8] The Lupus anticoagulant antibodies are ... Kay Thackray (2003). Sticky Blood Explained. Braiswick. ISBN 978-1-898030-77-5.. A personal account of dealing with the ... Antiphospholipid syndrome can cause arterial or venous blood clots, in any organ system, or pregnancy-related complications. In ...
A quick anti-Xa-activity-based whole blood coagulation assay for monitoring unfractionated heparin during cardiopulmonary ... Effects of heparin on polymerase chain reaction for blood white cells»։ J. Clin. Lab. Anal. 13 (3): 133-40։ 1999։ PMID 10323479 ... Higgins, C. (October 2007)։ «The use of heparin in preparing samples for blood-gas analysis»։ Medical Laboratory Observer ... CBS News, Blood-thinning drug under suspicion Archived 2012-10-23 at the Wayback Machine. ...
The gut mucosal cells do not get enough nourishment from arterial blood supply to stay healthy, especially in very premature ... Additional laboratory changes (metabolic and respiratory acidosis, disseminated intravascular coagulation). More recently, ... The underlying mechanism is believed to involve a combination of poor blood flow and infection of the intestines.[2] Diagnosis ... blood in the stool, or vomiting of bile.[1][2] ... infants, where the blood supply is limited due to immature ...
A scanning electron microscope image of normal circulating human blood. One can see red blood cells, several knobby white blood ... The coagulation system overlaps with the immune system. Some products of the coagulation system can contribute to the non- ... Identification and removal of foreign substances present in organs, tissues, blood and lymph, by specialized white blood cells ... All white blood cells (WBCs) are known as leukocytes. Most leukocytes differ from other cells of the body in that they are not ...
Roles of platelets and factor XI in the initiation of blood coagulation by thrombin. Thromb. Haemost.. July 2001, roč. 86, čís ... Amino acid sequence of human factor XI, a blood coagulation factor with four tandem repeats that are highly homologous with ...
Blood. 82 (5): 1532-7. PMID 8395910. "Entrez Gene: F2R coagulation factor II (thrombin) receptor". "José RJ, Williams AE, ... blood. 105 (8): 3178-84. doi:10.1182/blood-2004-10-3985. PMID 15626732. José RJ, Williams AE, Mercer PF, Sulikowski MG, Brown ... PAR-1 has multifaceted effects and plays a key role in mediating the interplay between coagulation and inflammation, which is ... Hoffman M, Church FC (Aug 1993). "Response of blood leukocytes to thrombin receptor peptides". Journal of Leukocyte Biology. 54 ...
blood coagulation. • positive regulation of Arp2/3 complex-mediated actin nucleation. • actin filament-based movement. • ... 97 (9): 2633-9. doi:10.1182/blood.v97.9.2633. PMID 11313252.. *^ a b She HY, Rockow S, Tang J, Nishimura R, Skolnik EY, Chen M ...
Bipolar coagulation[edit]. This method uses electric current to cauterize sections of the fallopian tube, with or without ... Major complications from laparoscopic surgery may include need for blood transfusion, infection, conversion to open surgery, or ... Monopolar coagulation[edit]. This method uses electric current to cauterize the tube, but also allows radiating current to ... further damage the tubes as it spreads from the coagulation site. The tubes may also be transected after cauterization.[24] The ...
... a condition of blood clotting in the blood vessels), coining the terms embolism and thrombosis.[56] He noted that blood clots ... claim made by the eminent French pathologist Jean Cruveilhier that phlebitis led to clot development and therefore coagulation ... He found an unusual number of white blood cells, and gave a detailed description in 1847 and named the condition as leukämie.[ ... Virchow correctly identified the condition as a blood disease, and named it leukämie in 1847 (later anglicised to leukemia).[34 ...
... which draws large numbers of white blood cells to the area and increases the regional blood flow. ...
Affecting blood pressure/(antihypertensive drugs): ACE inhibitors, angiotensin receptor blockers, beta-blockers, α blockers, ... Coagulation: anticoagulants, heparin, antiplatelet drugs, fibrinolytics, anti-hemophilic factors, haemostatic drugs. *HMG-CoA ... There are many variations in the routes of administration, including intravenous (into the blood through a vein) and oral ... There are three major categories of drug administration; enteral (by mouth), parenteral (into the blood stream), and other ( ...
A coagulation, also known as clot is a semi-solid substance that blood forms, especially when it is in air. When a person ... Proteins in the blood plasma, called coagulation factors or clotting factors, respond in a complex cascade to form fibrin ... Coagulation begins almost instantly after an injury to the blood vessel has damaged the endothelium lining the vessel. When ... A blood clot is also called a thrombus. The process is called coagulation. ...
"Biochemistry and physiology of blood coagulation". Thromb. Haemost. 82 (2): 165-74. பப்மெட்:10605701. ... "Blood 93 (6): 1798-808. பப்மெட்:10068650. ...
Routine blood tests (complete blood count, electrolytes, renal function, liver enzymes) are typically performed. Mast cell ... Additionally, it inhibits various proteins of the coagulation cascade, although effects of its deficiency on the development of ... Abdominal attacks have also been known to cause a significant increase in the patient's white blood cell count, usually in the ... In an emergency, fresh frozen blood plasma, which also contains C1-INH, can also be used. However, in most European countries, ...
... including disseminated intravascular coagulation (DIC), cellular necrosis (tissue death), low blood pressure, gangrene, and ... separation and removal of blood plasma from blood cells) and/or leukapheresis (removal of excess white blood cells) are often ... The bacteria cultures well on blood agar plates (heart infusion agar with 5% sheep or rabbit blood) and chocolate agar plates. ... In incidents where the patient is in full septic shock, whole blood smears may be effective. Immediate cleansing of wounds ...
blood coagulation. • proteolysis. • ER to Golgi vesicle-mediated transport. • blood coagulation, extrinsic pathway. ... Leytus SP, Foster DC, Kurachi K, Davie EW (September 1986). "Gene for human factor X: a blood coagulation factor whose gene ... Blood coagulation pathways in vivo showing the central role played by thrombin ... Kaul RK, Hildebrand B, Roberts S, Jagadeeswaran P (1986). "Isolation and characterization of human blood-coagulation factor X ...
The Indians hold this bark in high regard, and use it for all sorts of diarrhea, that are with blood [i.e., bloody] and without ... disseminated intravascular coagulation, leukopenia, and neutropenia. Some people who have developed TTP due to quinine have ... Blood glucose, electrolyte and cardiac monitoring are not necessary when quinine is given by mouth. ... Quinine can cause unpredictable serious and life-threatening blood and cardiovascular reactions including low platelet count ...
... mainly due to vasodilation of the peripheral small blood vessels), swelling of the conjunctiva, itching, and increased ...
敗血症常見的原發性感染來自下列位置:肺、腦、泌尿道、皮膚以及腹腔器官。血液培養(英语:Blood culture)可診斷出特定的病源菌,建議需在施打抗生素之前就取得血液檢體以提高陽性率,然而菌血症並
Because the reaction is slow, the Hb A1c proportion represents glucose level in blood averaged over the half-life of red blood ... Increased levels of this chemical are detected in the blood if red blood cells are being destroyed more rapidly than usual. ... Hemoglobin concentration measurement is among the most commonly performed blood tests, usually as part of a complete blood ... It measures the degree of glycation (glucose binding) to albumin, the most common blood protein, and reflects average blood ...
Several microangiopathic diseases, including disseminated intravascular coagulation and thrombotic microangiopathies, present ... Several blood tests involve red blood cells. These include a RBC count (the number of red blood cells per volume of blood), ... Main article: Blood transfusion. Red blood cells may be given as part of a blood transfusion. Blood may be donated from another ... Packed red blood cells (pRBC) are red blood cells that have been donated, processed, and stored in a blood bank for blood ...
Mathematical model of blood coagulation and the effects of inhibitors of Xa, Va:Xa and IIa. ... SBML L2V4 representation of Nagashima2002 - Simulating blood coagulation inhibitory effects. 58.52 KB. Preview , Download. ... and thrombin affect extrinsic pathway-triggered blood coagulation. Numerical simulation demonstrated a stronger inhibition of ... thrombin generation by fXa and thrombin inhibitors and has implications for the pharmacological regulation of blood coagulation ...
... it immediately contracts to limit the flow of blood. Within a few seconds cell-like blood platelets (about 1/8 the diameter of ... E. W. Davie, K. Fujikawa, M. E. Legaz and H. Kato, "Role of Proteases in Blood Coagulation," in Proteases and Biological ... Elliott D.L. (1978) Mathematical Models of Blood Coagulation Kinetics. In: Mohler R.R., Ruberti A. (eds) Recent Developments in ... If a mammalian blood vessel is severed, it immediately contracts to limit the flow of blood. Within a few seconds cell-like ...
Today marks the third lustrum of the annual international sympo- sium on blood transfus ... Coagulation and Blood Transfusion. Proceedings of the Fifteenth Annual Symposium on Blood Transfusion, Groningen 1990, ... Structural and Functional Properties of Recombinant Coagulation Factors A. Pavirani, S. Krishnan, S. Jallat, F. Perraud, A. ... Today marks the third lustrum of the annual international sympo- sium on blood transfusion, organized by the Rode Kruis ...
New subscriptions to Blood Coagulation & Fibrinolysis are managed through Lippincott Williams & Wilkins (LWW) online store. If ... Subscription renewals for Blood Coagulation & Fibrinolysis are managed through Lippincott Williams & Wilkins online store. If ...
Your account has been temporarily locked Your account has been temporarily locked due to incorrect sign in attempts and will be automatically unlocked in 30 mins. For immediate assistance, contact Customer Service: 800-638-3030 (within USA), 301-223-2300 (international) [email protected] ...
Blood coagulation is the process by which liquid blood changes into semisolid blood clots. It helps preventing blood loss from ... Shortly after, blood proteins, called coagulation factors or clotting factors, respond in a complex cascade to strengthen the ... When a blood vessel is damaged, small blood particles called platelets immediately form a plug at the site of injury. ...
A Laboratory Manual of Blood Coagulation Br Med J 1977; 1 :392 ... A Laboratory Manual of Blood Coagulation. Br Med J 1977; 1 doi ...
Coagulation Sample Collection for Coagulation Testing 1. Collection Tube. Blood should be collected in a blue-top tube ... Blood Specimens: Coagulation Blood Specimens: Coagulation. Sample Collection for Coagulation Testing. 1. Collection Tube. Blood ... Collection of blood for coagulation testing through intravenous lines that have been previously flushed with heparin should be ... Collection, Transport, and Processing of Blood Specimens for Testing Plasma-Based Coagulation Assays; Approved Guideline-Fifth ...
Blood coagulation is a basic physiological defense mechanism that occurs in all vertebrates to prevent blood loss following ... Blood coagulation is a basic physiological defense mechanism that occurs in all vertebrates to prevent blood loss following ... Comparative aspects of blood coagulation Vet J. 2004 Nov;168(3):238-51. doi: 10.1016/j.tvjl.2003.09.013. ... Thrombin converts soluble fibrinogen, via soluble fibrin monomers, into the insoluble fibrin that forms the matrix of a blood ...
6. Apparatus for testing blood coagulation comprising in combination: (a) a container for holding a blood sample; (b) an ... Method for measuring blood coagulation and device therefor. US4398894 *. Jun 8, 1981. Aug 16, 1983. Kabushiki Kaisha Kyoto ... A source of EMF 28 is connected between the two electrodes and the circuit is completed when a wet mass of blood coagulation ... The thread is of a material to which blood coagulation substances adhere, preferably a water wettable material such as glass, ...
... pathway of blood coagulation is associated with increased blood thrombogenicity and increases in markers of blood coagulation ... blood coagulation. Summary. Summary: The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble ... blood coagulation tests*hemostasis*hemorrhage*blood coagulation factors*anticoagulants*thrombin*thromboplastin* ... the blood-clotting assay is prudent to ensure dengue protease inhibitors do not interfere with the blood coagulation cascade ( ...
SEARCH RESULTS for: Blood Coagulation Factor [Drug Class] (630 results) *Share : JavaScript needed for Sharing tools. Bookmark ... ALPHANINE SD (coagulation factor ix (human)) kit. NDC Code(s): 63323-185-10, 68516-1002-2, 68516-3601-2, 68516-3602-2, view ...
Current aspects of blood coagulation, fibrinolysis, and platelets. [M -C Shen; C -M Teng; Akikazu Takada;] ... coagulation_disorders> # Blood Coagulation Disorders. a schema:Intangible ;. schema:name "Blood Coagulation Disorders"@en ;. . ... coagulation_congresses> # Blood--Coagulation--Congresses. a schema:Intangible ;. schema:name "Blood--Coagulation--Congresses"@ ... schema:name "Blood Coagulation"@en ;. schema:name "Blood--Coagulation"@en ;. ..
Best Blood Coagulation Disorders websites arranged logically for your convenience. Research health and wellness practices from ... Top / Health / Conditions and Illness / Blood Disorders / Blood Coagulation Access resources concerning hemostatsis. Learn how ... blood clots, view related illustrations, read about clotting disorders, and peruse research sources for more information. ...
Blood Coagulation and it Biochemistry and Molecular Biology. Our laboratory has focused on understanding the metal- and ... Airway, Breathing & Lung Allergies & Immune System Bone, Joint & Muscle Brain, Spine & Nervous System Cancers, Tumors & Blood ... remain major areas of interest to understand protein complex formation on membrane surfaces during blood coagulation. ... Center Balloon Weight Loss Program Benign Hematology Program Beth Israel Deaconess HealthCare Biologic Therapy Program Blood ...
Activated blood coagulation factor XI may refer to: Coagulation factor IXa, an enzyme Coagulation factor XIa, an enzyme This ... disambiguation page lists articles associated with the title Activated blood coagulation factor XI. If an internal link led you ...
Diseases : Blood Coagulation Disorders, Drug-Induced Toxicity , Fibrinogen: Elevated, Hypothyroidism. Problem Substances : ... Diseases : Blood Coagulation Disorders, Clotting, Hypertension. Therapeutic Actions : Dietary Modification: Mediterranean Diet ... 8 Abstracts with Blood Coagulation Disorders Research. Filter by Study Type. Human Study. ... 2 Problem Substances Researched for Blood Coagulation Disorders Name. AC. CK. Focus. ...
1634 Studies found for: Blood Coagulation Disorders: Clinical Trials. Also searched for Hemostatic disorder, Diseases, Trials ... Units of blood products used (red blood cells, plasma, platelets, prothrombin complex concentrate, fibrinogen, Factor VIIa, ... Blood product transfusion. 100. All. 18 Years and older (Adult, Senior). NCT02557672. 14-009579. August 2016. July 2018. July ... Number of blood products transfused. 82. All. 12 Years and older (Child, Adult, Senior). NCT02132208. CHRcitadelle-trauma-01. ...
Coagulation Factor IX Human. Coagulation factor X. target. DB13152. Coagulation Factor IX Human. Coagulation factor XI. target ... Coagulation factor VII human. Coagulation factor X. target. DB13150. Coagulation factor VII human. Coagulation factor IX. ... Coagulation Factor IX Human. Coagulation factor VII. target. DB13152. Coagulation Factor IX Human. Coagulation factor VIII. ... Coagulation Factor IX (Recombinant). Coagulation factor X. target. DB00100. Coagulation Factor IX (Recombinant). Coagulation ... -Stanching the free flow of blood from an injury remains a holy grail of clinical medicine. Controlling blood flow is ... As serine proteases play pivotal roles in blood coagulation, the innate immune system ... ... -- Some things are more fun to learn than others, and the coagulation cascade has traditionally been ranked among ... Bio-inspired bleeding control: Researchers synthesize platelet-like nanoparticles that can do more than clot blood. ( ...
Coagulation tests in 28 patients detected thrombocytopenia in 17, hypofibrinogenemia in ni … ... Patients with typhoid fever were studied to determine whether disseminated intravascular coagulation (DIC), circulating ... Studies of blood coagulation, bacteremia, and endotoxemia Arch Intern Med. 1978 Mar;138(3):407-10. doi: 10.1001/archinte.138.3. ... Coagulation tests in 28 patients detected thrombocytopenia in 17, hypofibrinogenemia in nine, and elevated titers of fibrinogen ...
Miscarriages Caused by Blood Coagulation Protein or Platelet Deficits * Sections Miscarriages Caused by Blood Coagulation ... Miscarriages Caused by Blood Coagulation Protein or Platelet Deficits) and Miscarriages Caused by Blood Coagulation Protein or ... Miscarriages Caused by Blood Coagulation Protein or Platelet Deficits. Updated: Dec 21, 2018 ... Bick RL, Hoppensteadt D. Recurrent miscarriage syndrome and infertility due to blood coagulation protein/platelet defects: a ...
... allowing them to see results from their at-home blood clotting tests on an iOS device. ... The app connects via Bluetooth to the CoaguChek XS meter, which patients use to test PT/INR, the time it takes for blood to ... Roche unveiled a new app for patients on anticoagulation therapy, allowing them to see results from their at-home blood ... Earlier this year, Roche launched the CoaguChek INRange system in Europe, which helps patients and doctors monitor coagulation ...
Blood coagulation is viewed as a process resulting in fibrin polymerization, which is considered as the first step towards ... In this work a mathematical model for blood coagulation induced by an activator source is presented. ... In this work a mathematical model for blood coagulation induced by an activator source is presented. Blood coagulation is ... A mathematical model of blood coagulation induced by activation sources. Georgy Th. Guria 1, , Miguel A. Herrero 2, and Ksenia ...
Young, COVID = Pathological Blood Coagulation. As I have previously stated, when it comes to COVID, there is not 1 virus, not 1 ... circulatory problems that stem from pathological blood coagulation. In technical medical terms, this coagulation (lumping and ... People suffering from this kind of pathological blood coagulation will experience oxygen deprivation (hypoxia or under ... the blood changes from a liquid to a gel or semi-solid state, forming a blood clot... ...
Essential Guide to Blood Coagulation has been updated to include the new anticoagulants and now has a dedicated chapter on ... Essential Guide to Blood Coagulation covers both the stable and the acute stages of hereditary and acquired bleeding and ... Essential Guide to Blood Coagulation, 2nd Edition. Jovan P. Antovic (Editor) , Margareta Blombäck (Editor) ... 16 Emergency conditions associated with coagulation: DIC, HIT and TTP/HUS, 182. Jovan P. Antovic and Margareta Holmström ...
Blood coagulation in anhepatic pigs: effects of treatment with the AMC-bioartificial liver.. Sosef MN1, Van De Kerkhove MP, ... The aim of this study was to assess the contribution of BAL treatment on blood coagulation parameters. Pigs were anesthetized ... Coagulation parameters studied concerned prothrombin time (PT), platelet count, the procoagulant system (factors (F)II, FV, ... This demonstrates that this bioartificial liver is capable of synthesizing coagulation factors. ...
To allow blood coagulation, in humans there exist 13 blood clotting proteins, called coagulation factors, which are usually ... A Mechanistic Model of the Blood Coagulation Cascade. Blood is an essential component in human life, whose primary functions ... Graphical representation of the blood coagulation cascade model considered in this work. Legend. Blue box: coagulation factor; ... Since the aim of this work is the investigation of blood coagulation in vivo, we exclude a small set of reactions given in [30 ...
... blood coagulation include Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes, A Microfluidic Flow ... Repeated Blood Collection for Blood Tests in Adult Zebrafish, Proliferation and Differentiation of Murine Myeloid Precursor ... Blood Collection for Biochemical Analysis in Adult Zebrafish, Procedure for Decellularization of Rat Livers in an Oscillating ... Evaluation of Blood Lactate and Plasma Insulin During High-Intensity Exercise by Antecubital Vein Catheterization, Direct ...
Parallel Studies of Complement and Blood Coagulation. VII. The Effect of Ethionine. Christine E. Rice, Paul Boulanger, P. J. G ... Parallel Studies of Complement and Blood Coagulation Message Subject (Your Name) has forwarded a page to you from The Journal ... 3. A moderate to marked prolongation of the coagulation time of the plasma was recorded in guinea pigs that had received ...
  • Antiplatelet drugs, such as aspirin, prevent blood cells called platelets from clumping together to form a clot. (
  • Within a few seconds cell-like blood platelets (about 1/8 the diameter of a red cell) touch the cut edges, break down, and aggregate into a plug-like mass. (
  • When a blood vessel is damaged, small blood particles called platelets immediately form a plug at the site of injury. (
  • The first Sino-Japanese symposium on Coagulation, Fibrinolysis and Platelets, originating from the Hamamatsu symposium, held in early 1990, was held in Hanchow, Mainland China in October, 1990. (
  • Fibrin sticks at the site of cut with platelets to make stable blood clot. (
  • Exposure of the blood to proteins such as tissue factor starts changes to blood platelets and the plasma protein fibrinogen, a clotting component. (
  • Although it behaves like a homogeneous fluid in large vessels such as arteries, human blood is really a suspension of solids (blood cells, platelets) that can alter their characteristics in response to chemical and physical provocation. (
  • The process begins when blood-clotting proteins bind to the membranes of activated platelets. (
  • There is ongoing debate whether an increase in the number of blood cells (especially platelets) is solely responsible for thrombotic complications observed in the course of this disease [ 4 , 5 ]. (
  • The results showed that Cd intoxication impaired hepatorenal function and significantly prolonged prothrombin time and activated partial thromboplastin time and decreased fibrinogen level, red blood cells and platelets counts, hemoglobin concentration, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, and mean corpuscular hemoglobin concentration. (
  • Fibrin are long strands of protein which then form a mesh network securing the platelets laid down in the previous phases of hemostasis and trapping other blood cells and components to form a blood clot . (
  • The reason for the thrombosis could be excessive activation of the coagulation factors and platelets. (
  • According to Prof. Violi, these "reactive oxygen species" not only activate blood clotting and platelets but also cause the blood vessels to constrict (vasoconstriction). (
  • The values for coagulation indices, clotting time, and Russel viper venom time were consistent with decreased thrombotic tendency of platelets from animals on the SSO diet relative to the low fat, REF diet animals, while an increased tendency to thrombosis was observed with SF-fed marmosets. (
  • In this paper, we describe how the circulating blood cells - monocytes, platelets, neutrophils and their microparticles - co-operate in regulating the expression, availability and activity of monocyte-derived TF. (
  • The reason why this is so hinges on the several thrombin-dependent positive feedback reactions of the coagulation cascade, including the activation of FVIII and FV in addition to the potent activation of platelets. (
  • Conclusions In this population-based cohort, we found associations of long-term exposure to PM with markers of inflammation (hs-CRP) and coagulation (platelets). (
  • Independent of adding exogenous tissue factor (TF), human blood treated in vitro with corn trypsin inhibitor (CTI, to block Factor XIIa) will generate thrombin after an initiation time ( T i ) of 1 to 2 hours (depending on donor), while activation of platelets with the GPVI-activator convulxin reduces T i to ~20 minutes. (
  • Next, we showed that "contact activation," despite use of the best available inhibitor (CTI) to prevent it, builds up enough autocatalytic strength to trigger coagulation without exogenous TF, particularly upon activated platelets. (
  • 2016 -06-09 Hysteresis-like binding of coagulation factors x/xa to procoagulant activated platelets and phospholipids results from multistep association and membrane-dependent multimerization (Podoplelova et al. (
  • In contrast, regular exercise causes decreased activity of platelets and the coagulation system resulting in an improvement in haemostatic balance. (
  • The mechanism of coagulation involves activation, adhesion and aggregation of platelets, as well as deposition and maturation of fibrin. (
  • Exposure of blood to the subendothelial space initiates two processes: changes in platelets, and the exposure of subendothelial tissue factor to plasma factor VII, which ultimately leads to cross-linked fibrin formation. (
  • Activated platelets release the contents of stored granules into the blood plasma. (
  • New subscriptions to Blood Coagulation & Fibrinolysis are managed through Lippincott Williams & Wilkins (LWW) online store. (
  • Subscription renewals for Blood Coagulation & Fibrinolysis are managed through Lippincott Williams & Wilkins online store. (
  • The dysfunction of the blood coagulation-fibrinolysis system is a salient characteristic of PE that varies in severity, and necessitates different treatments. (
  • They active other coagulation factors within the body and these help to arrest clotting, resulting in fibrinolysis(Brand,1985). (
  • Changes in platelet function, blood coagulation and fibrinolysis during insulin-induced hypoglycaemia in juvenile diabetics and normal subjects. (
  • FIELD OF THE INVENTION This invention relates to detecting changes in viscosity of biologic fluid test samples, e.g., detecting coagulation and coagulation-related activities including agglutination and fibrinolysis of human blood test samples, and more particularly to improved methods and apparatus for obtaining a coagulation time of a blood test sample. (
  • There are surprisingly few interventional studies to assess the true effects of estrogen-progestin regimens on blood coagulation and fibrinolysis, and the impact of the route of estrogen administration on hemostasis has not been well documented. (
  • Blood coagulation and fibrinolysis of the newborn viewed äs perinatal factors. (
  • Alterations of fibrinolysis and blood coagulation induced by exercise, and the role of beta-adrenergic receptor-stimulation. (
  • Learn how blood clots, view related illustrations, read about clotting disorders, and peruse research sources for more information. (
  • RMS due to blood protein or platelet defects may come about through either of two mechanisms: (1) disorders associated with a hemorrhagic tendency or (2) defects associated with a thrombotic tendency. (
  • Essential Guide to Blood Coagulation covers both the stable and the acute stages of hereditary and acquired bleeding and thrombotic disorders. (
  • In order to diagnose disorders in these coagulation factors, different biological tests have been developed (prothrombin time, activated partial thromboplastin time, activated cephalin clotting time, etc. (
  • Coagulation disorders can lead to an increased risk of haemorrhage or thrombosis. (
  • Blood Coagulation Disorders" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (
  • BLOOD PROTEIN DISORDERS or nutritional conditions. (
  • This graph shows the total number of publications written about "Blood Coagulation Disorders" by people in Harvard Catalyst Profiles by year, and whether "Blood Coagulation Disorders" was a major or minor topic of these publication. (
  • Below are the most recent publications written about "Blood Coagulation Disorders" by people in Profiles. (
  • Hemophilia A, one of the most common genetic bleeding disorders, is caused by various mutations in the blood coagulation factor VIII ( F8 ) gene. (
  • Coagulopathies are group of bleeding disorders that affect blood clotting process in the body. (
  • Coagulation disorders lead to excessive or prolonged bleeding after an injury (Thijs,1993). (
  • These tests determine the quantities of coagulation factors, because these disorders are caused when one or more of coagulation factors are increased, low, or absent(Fihn,1995). (
  • They are also aid in the diagnosis of bleeding disorders and monitor the patient's blood clot status and effectiveness of anticoagulant therapy (Fihn,1995). (
  • Disorders of coagulation can accelerate to an expanded risk of bleeding (hemorrhage) or obstructive clotting (thrombosis). (
  • Journal of Blood Disorders & transfusion publishs the work related all blood coagulation diseases of all major clinical and medical classifications. (
  • Journal of Blood Disorders & transfusion have a world class Editorial Board and maintains its quality publication with support of its editors in Peer review process. (
  • Understanding blood flow and coagulation is crucial to treating blood disorders such as hemophilia and thrombosis, and to dealing with diseases such as AIDS, malaria, and diabetes that have hematologic consequences. (
  • Essential advisor to Blood Coagulation covers either the good and the intense phases of hereditary and purchased bleeding and thrombotic disorders. (
  • These types of disruption is seen with various blood clotting disorders. (
  • The internationally renowned expert has an assumption of why COVID-19 can so often lead to coagulation disorders. (
  • In addition to Prof. Violi, several other scientists also point to coagulation disorders in their works published in the Thieme medical journal Thrombosis and Haemostasis and recommend appropriate treatment for these patients. (
  • Bleeding disorders are a group of disorders that result when the blood cannot clot properly. (
  • Disorders of coagulation are disease states which can result in problems with hemorrhage, bruising, or thrombosis. (
  • Site offers a wide range of information about topics related to the pathophysiology, pharmacology, and clinical aspects of bleeding, coagulation, and hemostasis. (
  • Bovine thrombin is a topical thrombin indicated to aid hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques (like suture, ligature, or cautery) is ineffective or impractical [FDA Label]. (
  • Blood Coagulation Testing is a method used for diagnostics of the hemostasis system. (
  • Blood coagulation is an essential part of hemostasis, the discontinuance of blood loss from a damaged vessel, wherein a damaged blood vessel wall is secured by a platelet and fibrin-containing clot to quit bleeding and start repair of the damaged vessel. (
  • Hemostasis is the mechanism to prevent blood loss. (
  • There are four main phases to hemostasis with the blood coagulation phase following vascular constriction (first phase) and then the platelet plug (second phase). (
  • We developed hepatocyte crush method: (HeCM) using a monopolar soft-coagulation devices for not only hemostasis, but also detachment of blood vessels. (
  • Besides the plasma coagulation factors, undisturbed hemostasis is dependent on thrombocytes and their normal functions. (
  • We conclude that oral estrogen/progesterone replacement therapy may result in coagulation activation and increased fibrinolytic potential, whereas opposed transdermal estrogen appears without any substantial effects on hemostasis. (
  • STUDY SELECTION: Articles were selected that provided data on the effects of colloids on hemostasis and postoperative blood loss in humans. (
  • It potentially results in hemostasis, the cessation of blood loss from a damaged vessel, followed by repair. (
  • Secondary hemostasis occurs simultaneously: additional coagulation (clotting) factors beyond factor VII (listed below) respond in a cascade to form fibrin strands, which strengthen the platelet plug. (
  • The coagulation cascade of secondary hemostasis has two initial pathways which lead to fibrin formation. (
  • Under-filling of citrate collection tubes results in an increased anticoagulant-to-blood ratio and can extend clot-based coagulation assays. (
  • Lupus anticoagulants (LA) are are nonspecific antibodies that extend clot-based coagulation assays as the result of their interaction with phospholipid in the reaction mixture. (
  • Since the time a vessel is allowed to leak or the ease with which it may be pathogenically blocked have a great bearing on the survival of the human organism, coagulation assays, particularly those which deal with the rate of clot formation, are useful in many respects. (
  • Coagulation assays on-scene were comparable between the TXA and C. Prehospital hyperfibrinolysis was blunted in all 4 patients in the TXA group. (
  • Thrombin converts soluble fibrinogen, via soluble fibrin monomers, into the insoluble fibrin that forms the matrix of a blood clot as well as exerting positive-feedback regulation that effectively promotes additional thrombin generation that facilitates the rapid development of a thrombus. (
  • Levothyroxine replacement therapy increases coagulation (fibrinogen) following initiation of treatment. (
  • Coagulation tests in 28 patients detected thrombocytopenia in 17, hypofibrinogenemia in nine, and elevated titers of fibrinogen-related antigens in 20. (
  • Coagulation parameters studied concerned prothrombin time (PT), platelet count, the procoagulant system (factors (F)II, FV, FVII, FVIII and fibrinogen), anticoagulant system (AT III), fibrinolytic system (t-PA, PAI-1) as well as markers of coagulation factor activation (TAT complexes, prothrombin fragment F1 + 2). (
  • The optimum pH for this coagulation was determined for 3 of these, and was found in each case to be approximately pH 6.5, the same as that for the action of thrombin on fibrinogen. (
  • Standard laboratory tests (blood count, international normalized ratio (INR) / prothrombin time (PT), activated partial thromboplastin time (aPTT) fibrinogen concentration (FIB) were routinely available for guiding transfusion of coagulation blood products. (
  • The investigators expect to measure platelet number, blood cells counts, and levels of fibrinogen, thrombin-antithrombin complex, tissue plasminogen activator, plasminogen activator inhibitor, and factor VII of rats that will be exposed to concentrated New York City particles and filtered air for 6 hours. (
  • As a result, blood coagulation status can be measured by relating the time scale of speckle intensity fluctuations with clinically relevant coagulation metrics including clotting time and fibrinogen content. (
  • Our results report a close correlation between coagulation metrics measured using LSR and conventional coagulation results of activated partial thromboplastin time, prothrombin time and functional fibrinogen levels, creating the unique opportunity to evaluate a patient's coagulation status in real-time at the point of care. (
  • Evidence for disseminated intravascular coagulation was inconclusive due to the presence of normal to elevated fibrinogen levels, relatively low levels of circulating fibrin split products, and the lack of widespread fibrin thrombus deposition. (
  • The coagulation system was evaluated using a routine coagulation function test performed in the hospital laboratory before coronary angiography, and measurements included prothrombin time, international normalized ratio, activated partial thromboplastin time, fibrinogen time, and thrombin time. (
  • A prolongation of the activated partial thromboplastin time was found after radiation alone, although the fibrinogen concentration, the substrate of the coagulation cascade, was increased as well. (
  • Applying mixed regression models, we analysed associations of long-term (mean of 365 days prior to blood draw) particle exposure at each participant's residence with the level of high-sensitivity C reactive protein (hs-CRP), fibrinogen, platelet and white cell count (WCC), adjusting for short-term PM exposure (moving averages of 1-7 days), personal characteristics, season, ambient temperature (1-5 days), ozone and time trend. (
  • Shortly after, blood proteins, called coagulation factors or clotting factors, respond in a complex cascade to strengthen the platelet plug. (
  • The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot. (
  • Prothrombin is administered as part of a cocktail containing several coagulation factors. (
  • Treatment of anhepatic pigs with the AMC-BAL based on freshly isolated porcine hepatocytes does not result in an improved coagulation state due to extensive consumption of clotting factors. (
  • However, increased levels of TAT complexes and prothrombin fragments F1 + 2 during treatment of anhepatic pigs indicate synthesis and direct activation of coagulation factors, leading to thrombin generation. (
  • This demonstrates that this bioartificial liver is capable of synthesizing coagulation factors. (
  • Blood coagulation factors and other proteins, with modulatory effects or modulated by the coagulation cascade have been reported to affect the pathophysiology of the central nervous system (CNS). (
  • De Luca C, Virtuoso A, Maggio N, Papa M. Neuro-Coagulopathy: Blood Coagulation Factors in Central Nervous System Diseases. (
  • The coagulation mechanism implies a complex series of cascading enzymatic reactions involving proteins, referred to as coagulation factors. (
  • Blood coagulation factors are proteins that released along with blood proteins. (
  • Coagulations tests such as ThrombinTime (TT) ,PT (Prothrombin Time) and Activated partial thromboplastin time (APTT) are performed to determine the defects associated with coagulation factors of the coagulation cascade(Fihn,1995). (
  • Patient 1 had normal TT, PT and APTT .Patient had adequate levels of coagulation factors in the extrinsic, intrinsic and common pathways. (
  • Subject matter wherein the peptide composition is related to fibrinopeptides, blood-coagulation factors or derivative. (
  • To Analyze the Global Blood Coagulation Testing Market based on various factors- price analysis, supply chain analysis, porters five force analysis etc. (
  • This study testified that HCT, flow velocity, and tubing size were substantial factors affecting the backscattering properties during flowing blood coagulation. (
  • The discussions of biochemical principles of fibrin formation (Blomback), interactions of soluble clotting factors (Denson, Hemker, and Hanahan), and the structure of individual clotting factors (Esnouf and Magnusson) are sophisticated considerations of highly specialized subjects of coagulation. (
  • It covers the volumes, prices, historical growth and future perspectives in the Blood Coagulation Analyzer market and further lays out an analysis of the factors influencing the supply/demand for Blood Coagulation Analyzer, and the opportunities/challenges faced by industry participants. (
  • The coagulation process involves 12 clotting factors (11 different specialized chemicals and calcium) which act on each other to lead to clot formation and this is known as the coagulation cascade . (
  • Extrinsic pathway which is mediated by factors outside of the blood released during injury. (
  • Intrinsic pathway which is mediated by factors within the blood coming into contact with the damaged area. (
  • As a consequence, the concentration of coagulation factors in the blood is reduced leading to a generally increased risk of haemorrhage. (
  • The "Coagulation Factors 2009: Target Pipeline and Corporate Benchmark Analysis" report is the most complete and up-to-date evaluation and assessment of the recombinant and plasma-derived coagulation factor pipelines. (
  • The authors analyze and assess the target pipeline for each of the coagulation factors used for systemic and topical administration. (
  • Technologies used for creation of next generation coagulation factors are discussed and assessed. (
  • Replacement of plasma-derived coagulation factors by marketed recombinant molecules is ongoing and will further increase by new recombinant coagulation factors in development. (
  • Blood coagulation analyzer Worldwide Market Research Report examined the growth rate and the Blood coagulation analyzer Market value based on industry dynamics, growth-driving factors. (
  • Blood coagulation analyzer Market report serves a clear insight about the prominent factors that are witnessed to transform the worldwide market in the upcoming years. (
  • Coagulation factors are generally indicated by Roman numerals, with a lowercase a appended to indicate an active form. (
  • The coagulation factors are generally serine proteases (enzymes), which act by cleaving downstream proteins. (
  • The coagulation factors circulate as inactive zymogens. (
  • These proteins, in fact, showed peculiar properties, being able to interfere with synaptic homeostasis other than coagulation itself. (
  • Endogenous substances, usually proteins, that are involved in the blood coagulation process. (
  • Background Coagulation during cardiopulmonary bypass (CPB) traditionally has been attributed to activation of the contact system of plasma proteins and the intrinsic coagulation pathway by blood contact with negatively charged surfaces not lined by endothelium. (
  • During CPB, the contact system of plasma proteins 3 and the intrinsic coagulation pathway are stimulated by contact with large areas of nonendothelialized biomaterials in the extracorporeal circuit. (
  • Once clot is formed, other blood coagulation proteins take place in the body(Thijs,1993). (
  • Gamma globulins, Ig's for short, are a class of proteins found in the blood of humans and animals. (
  • Defined as the liquid component found in blood, serum is comprised of electrolytes, immunoglobulin, and proteins. (
  • Tajkhorshid is currently using his lubed-up model to pursue an even more ambitious goal: simulating how different coagulation proteins form complexes on the membrane surface in order to become fully activated, thereby driving the coagulation cascade forward. (
  • The most likely causes of the hemorrhagic tendencies of this disease in infected monkeys were thrombocytopenia and decreased synthesis of coagulation and other plasma proteins due to severe hepatocellular necrosis. (
  • The market size of recombinant and plasma-derived coagulation factor products exceeded US$ 7.5 bln in 2008, the majority (US$ 5.5 bln) generated by recombinant proteins. (
  • -- Some things are more fun to learn than others, and the coagulation cascade has traditionally been ranked among the less fun. (
  • In this work we present coagSODA, a CUDA-powered computational tool that was purposely developed for the analysis of a large mechanistic model of the blood coagulation cascade (BCC), defined according to both mass-action kinetics and Hill functions. (
  • Their role is to activate steps in the process called coagulation cascade(Brandt JT,1985). (
  • Emad Tajkhorshid, PhD , professor of biochemistry, biophysics, and pharmacology at the University of Illinois, has been using molecular dynamics (MD) modeling to simulate the earliest stages in the coagulation cascade. (
  • The pathways involved the series of chemical reactions known as the coagulation cascade. (
  • If one chemical (blood clotting factor) is missing or fails to act appropriately, the entire cascade can be disrupted and the formation of a blood clot may not occur or arise very slowly. (
  • This is the start of the coagulation cascade. (
  • The formation of fibrin during haemostasis stems from local exposure of TF (tissue factor) and the consequential activation of the coagulation cascade leading to the generation of thrombin at the site of injury. (
  • TF serves as a cellular receptor and cofactor for plasma FVIIa, the enzyme initiating the coagulation protease cascade, leading ultimately to the generation of thrombin and fibrin. (
  • The protein Tissue Factor (TF) initiates this cascade when blood vessels are disrupted, but how this cascade is triggered in the absence of exogenous TF remains the subject of much debate. (
  • It was previously thought that the two pathways of coagulation cascade were of equal importance, but it is now known that the primary pathway for the initiation of blood coagulation is the tissue factor (extrinsic) pathway. (
  • The coagulation cascade is therefore classically divided into three pathways. (
  • The main role of the tissue factor pathway is to generate a "thrombin burst", a process by which thrombin, the most important constituent of the coagulation cascade in terms of its feedback activation roles, is released very rapidly. (
  • In a "Letter to the Editor" published recently in the medical journal "Thrombosis and Haemostasis" (Thieme, New York, 2020), clinical pathologists point out that COVID-19 has an effect on the blood coagulation of patients. (
  • For this reason, the D-dimer value is generally determined in case of any suspicion of pulmonary embolism, leg vein thrombosis or disseminated intravascular coagulation (DIC). (
  • Researchers within The Didar Lab and the Michael G. DeGroote Institute for Infectious Disease Research , created a novel surface modification process applied to catheters to lower the risk of blood thrombosis. (
  • The CVD method is a simple, straightforward, and non-invasive procedure, with the potential to not only prevent catheter thrombosis, but also thrombosis associated with other widely used blood contacting medical devices. (
  • Blood-contacting medical devices such as catheters, heart valves and vascular grafts are prone to thrombosis, which can lead to thromboembolic complications and device failure," explained Maryam Badv, PhD candidate, School of Biomedical Engineering and lead author on the study. (
  • Recent reports have reevaluated the relative roles of the intrinsic and extrinsic coagulation pathways during clinical cardiac surgery 5 6 and have provided indirect evidence that the extrinsic coagulation pathway is activated during open heart surgery. (
  • The report studies the industry for (Blood Coagulation Analyzer Market) mainly covers 13 Topics acutely display the global Blood Coagulation Analyzer Market. (
  • The present study began with mathematical modeling of how inhibitors of both factor Xa (fXa) and thrombin affect extrinsic pathway-triggered blood coagulation. (
  • Recent studies have focused on the possible role of the extrinsic coagulation pathway during cardiac surgery. (
  • We postulated that the wound activates the extrinsic coagulation pathway during CPB by producing procoagulant cells and enzymes that enter the general circulation. (
  • Conclusions These data provide direct evidence of TF expression, activation of the extrinsic coagulation pathway, and thrombin formation in the surgical wound. (
  • Evidence for stimulation of the extrinsic coagulation pathway during CPB is largely circumstantial. (
  • A coagulation analyzer is a type of automated analyzer that measures blood platelet levels, coagulation pathway speed, and thrombolin and thromboplastin levels in a blood sample. (
  • This pathway is triggered by the blood coming into contact with the collagen into damaged vessel wall. (
  • 0.05), in which the blood coagulation pathway was significantly enriched. (
  • The results demonstrated stronger inhibition of endogenous thrombin potential by argatroban than by DX-9065a, especially when coagulation was initiated at higher tissue factor concentrations, while argatroban appeared to be slightly less potent in its ability to prolong clot time. (
  • this polymerizes into fibrin strands which reinforce the platelet plug and form a blood clot. (
  • The reaction sequence is initiated by the expression of tissue factor on the surface of activated cells and results in the generation of thrombin, the most important enzyme in blood clot formation. (
  • On the assumption that the processes which lead to the development of an in vitro clot are analogous to those which produce in vivo thrombi, techniques have been developed for in vitro coagulation studies. (
  • Due to this deficiency, the blood cannot clot properly and the patients that present this disease are prone to prolonged or excessive bleeding. (
  • The app connects via Bluetooth to the CoaguChek XS meter, which patients use to test PT/INR, the time it takes for blood to clot. (
  • the blood changes from a liquid to a gel or semi-solid state, forming a blood clot. (
  • 14 the tilt-tube method, where the tube containing a blood sample is tilted back and forth until a fibrin network is formed, and the wire-loop technique, where a wire loop is passed through the mixture until a clot forms and adheres to the loop. (
  • Most systems currently measuring the clotting time use one of the two following principles: the immobilization of a moving probe immersed in the sample when a clot is formed 15 , 16 or the change in optical density of the mixture when coagulation has occurred. (
  • The blood sample will completely contact with coagulant and clot within 5-8mins. (
  • Blood coagulation is the process of forming a blood clot . (
  • Nevertheless, the net result of all the processes is to conclude with the formation of a blood clot. (
  • During blood coagulation, changes in the viscoelastic properties of the clot restrict Brownian displacements of light scattering centers within the sample, altering the rate of speckle intensity fluctuations. (
  • CTI-treated human blood will clot in vitro due to the combined activity of XIIa and XIa, a process enhanced by platelet activators and which proceeds in the absence of any evidence for kinetically significant blood borne tissue factor. (
  • The problem is specifically with Prothrombin Time values, a measure of how long it takes blood to clot, which the INRatio meter software cannot reliably determine, according to the government's complaint. (
  • Coagulation, also known as clotting, is the process by which blood changes from a liquid to a gel, forming a blood clot. (
  • Essential Guide to Blood Coagulation has been updated to include the new anticoagulants and now has a dedicated chapter on antiplatelet drugs. (
  • All heatstoke animals displayed and activated coagulation evidenced by increased prothrombin time (PT), activated partial thromboplastin time (aPTT), D-dimer, and decreased platelet count, protein C. Furthermore, the animals displayed systemic inflammation evidenced by increased the serum levels of cytokines interleukin-1ß (IL-1ß), tumor necrosis factor α (TNF-α) and malondialdehyde (MDA). (
  • A concise full-color overview of the mechanisms of blood ailments and issues - in accordance with a Harvard clinical university hematology course2015 Doody's center name! (
  • This new report provides analyses of 100 major and emerging suppliers of immunodiagnostics, microbiology, cancer diagnostic, molecular diagnostic, hematology, coagulation and blood banking instruments and reagents. (
  • This study demonstrates differential inhibition of thrombin generation by fXa and thrombin inhibitors and has implications for the pharmacological regulation of blood coagulation by the anticoagulant protease inhibitors. (
  • Still another object is to provide test methods and apparatus for determination of blood coagulation time which may be essentially fully automated, being subject little, if at all, to human error or judgment. (
  • A highly sensitive label-free assay for the determination of blood coagulation Factor XIII activity is demonstrated through the controlled assembly of peptide-functionalized gold nanoparticles (AuNPs). (
  • Evacuated collection tubes must be filled to completion to ensure that a 9:1 blood-to-anticoagulant ratio is achieved. (
  • The sample should be mixed immediately by three to six complete gentle end-over-end inversions to ensure adequate mixing of the anticoagulant with the blood. (
  • Moreover, according to the International Self-Monitoring Association of Oral Anticoagulated Patients (ISMAAP), nearly four milion people are under oral anticoagulant therapy in Europe and need to monitor their coagulation time daily to self-adjust the dosage of their treatment and thus maintain the optimal therapeutic range. (
  • The DOJ indicates that from 2008 to 2016, Alere knowingly sold defective INRatio-blood coagulation monitors used by Medicare patients taking anticoagulant drugs. (
  • For patients, blood coagulation monitors are essential because they assist patients in taking the proper amount of anticoagulant drugs. (
  • The dosage of anticoagulant drugs is crucial, and receiving too many anticoagulant drugs can cause major bleeding, while too little can cause blood clots and strokes. (
  • This study was designed to determine whether blood contact with the surgical wound activated monocytes to express TF and stimulated the extrinsic coagulation system to produce thrombin during clinical cardiac surgery. (
  • The extrinsic-intrinsic model of blood clotting has in recent years given way to a new cell-based model of clotting. (
  • Blood thinners are medicines that prevent blood clots from forming. (
  • They also keep existing blood clots from getting larger. (
  • Blood Thinners: Can I Still Get Blood Clots? (
  • Blood coagulation is the process by which liquid blood changes into semisolid blood clots. (
  • This can be potentially dangerous, because when blood coagulates or clots, it can get stuck and prevent blood flow. (
  • When blood clots, it can't enter the capillary system to facilitate the exchange of oxygen and carbon dioxide. (
  • Blood Coagulation (thrombogenesis) is the intricate process by which blood forms clots. (
  • Hyperactivity of the blood coagulation process (thrombophilia) could explain why many patients suffer a heart attack or stroke, which are caused by blood clots in the coronary or cerebral arteries. (
  • The protein is increasingly produced when clots have already formed in the blood vessels. (
  • Takeda tapped Roche's Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies. (
  • Methods and Results Blood samples taken from 20 consenting patients who had elective cardiac surgery were assayed for peripheral blood mononuclear cell tissue factor (TF) expression, plasma F1.2, and factor VII and VIIa concentrations. (
  • Tissue factor (TF) can also stimulate the transcription of the gene encoding VEGF-A. The relationship between coagulation and angiogenesis in myeloproliferative neoplasms is not fully understood. (
  • When the blood vessel wall is damaged, the tissue releases tissue factor also known as tissue thromboplastin ( Factor III ). (
  • Combination treatment with Gua Sha and Blood-letting causes attenuation of systemic inflammation, activated coagulation, tissue ischemia and injury during heatstroke in rats. (
  • Gua Sha combined with Blood-letting after heatstroke may improve survival by ameliorating systemic inflflammation, hypercoagulable state, and tissue ischemia and injury in multiple organs. (
  • The transmembrane glycoprotein TF (tissue factor) plays an essential role in haemostasis as the principal initiator of blood coagulation. (
  • This invention provides a method of inhibiting coagulation in extracorporeal circulation in a subject, comprising administration of a therapeutically effective amount of a monoclonal antibody which inhibits the ability of tissue factor to bind to factor VII/VIIa. (
  • The method prevents complex formation between tissue factor and factor VII/VIIa and thus inhibits coagulation of blood in extracorporeal procedures such as cardiopulmonary bypass and other shunt procedures. (
  • The process includes the following steps: Following damage to the blood vessel, FVII leaves the circulation and comes into contact with tissue factor (TF) expressed on tissue-factor-bearing cells (stromal fibroblasts and leukocytes), forming an activated complex (TF-FVIIa). (
  • It is also indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding or who require rapid reversal of therapy. (
  • Intestinal bleeding, however, did not correlate with abnormalities of coagulation tests. (
  • Also, the ameliorating and counteracting effects of CAPE on different disease modalities of hematological, blood coagulation, and vascular abnormalities have recently been emerged. (
  • The disease in infected animals was also characterized by the development of hypotension and coagulation abnormalities as indicated by severe thrombocytopenia and prolongation of the activated partial thromboplastin time. (
  • 23230 B Claims ABSTRACT OF THE DISCLOSURE A freshly drawn sample of venous blood is placed in a container, such as a hypodermic syringe, and a thread is moved lengthwise through the sample until a substantially continuous mass of fibrin and/or red blood cells form thereon, marking the endpoint of the test. (
  • Deerfield Beach, FL -- ( SBWIRE ) -- 01/01/2018 -- The report that is written on the titled Blood Coagulation Analyzer Market 2017 covers all the aspects of the global market study. (
  • Blood coagulation is a basic physiological defense mechanism that occurs in all vertebrates to prevent blood loss following vascular injury. (
  • The realization that TF of blood vessels is predominantly localized in adventitia, deeply hidden away from the vessel lumen, prompted the launching of an 'envelope' theory, entailing the notion of TF as a haemostatic envelope encapsulating the vascular bed, already present for initiating blood clotting should the integrity of the vasculature be compromised [ 8 ]. (
  • Elliott D.L. (1978) Mathematical Models of Blood Coagulation Kinetics. (
  • The "Platelet-Plasma" model lays the groundwork for integration of coagulation reaction kinetics and donor specific descriptions of platelet function. (
  • Reasons that cause coagulation issues include liver disease, thrombophilia and hemophilia. (
  • Additionally some unwanted interactions of the blood with artificial surfaces may cause coagulation activation, blood platelet aggregation [ 5 ] or proinflammatory effects [ 6 , 7 ]. (
  • This lets him cover a larger territory in the circulatory system at a longer timescale, modeling changes in blood viscosity and simulating the kinds of abnormal red blood cell aggregation that occurs in diseases such as atherosclerosis, AIDS, myeloma, and diabetes mellitus. (
  • Patients with elevated hematocrits have a relatively low amount of plasma for a given whole blood (collection) volume. (
  • An onion-olive-oil combination reduces arterial blood pressure, plasma viscosity and hematocrit, indicating the cardiovascular benefits of a Mediterranean diet. (
  • 3. A moderate to marked prolongation of the coagulation time of the plasma was recorded in guinea pigs that had received repeated doses of ethionine. (
  • A surface plasmon resonance (SPR) apparatus was used to investigate blood plasma coagulation in real-time as a function of thromboplastin and heparin concentrations. (
  • Nine of the 17 venoms here tested were found capable of coagulating citrated blood or plasma. (
  • HES200 has a greater effect on blood cells and plasma separation than does HES130. (
  • Transfusion rates of allogeneic blood products (Red blood cells = RBC, Fresh frozen plasma = FFP, Platelet concentrates = PLT) and patient adverse outcomes in two cohorts before and after the implementation of a SONOCLOT based coagulation management algorithm were evaluated on an observational basis in 1754 patients undergoing different types of cardiac surgery. (
  • BACKGROUND OF THE INVENTION Blood coagulation is a complex chemical and physical reaction that occurs when blood (herein, 'blood' shall mean whole blood, citrated blood, platelet concentrate, plasma, or control mixtures of plasma and blood cells, unless otherwise specifically called out, and may include heparinized blood) comes into contact with an activating agent, such as an activating surface or an activating agent. (
  • DUBLIN, June 7, 2021 /PRNewswire/ -- The "Blood Plasma Products Market in India 2021" report has been added to's offering. (
  • Biochemical markers evidenced by cellular ischemia and injury/dysfunction included increased plasma levels of blood urea nitrogen (BUN), creatinine, serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT), and alkaline phosphatase (ALP) were all elevated during heatstroke. (
  • however, in case of any injury disrupting the endothelium, it can no longer detain plasma factor VII [FVII (coagulation factor VII)] or FVIIa (activated FVII) from binding to TF. (
  • Although not yet proven, the normally occurring trace amounts of FVIIa in the circulating plasma might provide for the enzymatic potential of the very first FVIIa-TF complexes, formed on injury-related exposure to the blood of extravascular TF sites, thus initiating the cascading process. (
  • Clotting of blood involves a series of reactions wherein at each step an inactive zymogen is converted to an active enzyme by the product of the previous step, sometimes in plasma and usually on efficient catalytic surfaces provided by the activating platelet. (
  • Effects of different plasma substitutes on blood coagulation: a comparative review. (
  • OBJECTIVE: To compare the effects of different colloid plasma substitutes on blood coagulation and postoperative blood loss. (
  • Changes in platelet function and some plasma parameters of coagulation exhibit a significant correlation to base excess, pH and lactate. (
  • This report offers key statistics on the market status of the Blood Coagulation Analyzer Manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the Blood Coagulation Analyzer Industry. (
  • Additionally, the Blood Coagulation Analyzer industry development trends and marketing channels are analysed. (
  • This estimation covers Blood coagulation analyzer industry key vendor's examination based on the company's synopsis, Blood coagulation analyzer company profiles, financial study, market revenue, and opportunities by leading topographical regions. (
  • The Blood coagulation analyzer industry advancement trends and advertising channels have also been studied. (
  • The Blood coagulation analyzer research analysis includes all facets of the Blood coagulation analyzer market worldwide, which begins with the definition of the Blood coagulation analyzer industry and progress towards Blood coagulation analyzer market segments. (
  • The leading manufacturers influence the operations in the Blood coagulation analyzer industry impute to their strong geographical extend and huge production facilities. (
  • The aim of this study was to assess the contribution of BAL treatment on blood coagulation parameters. (
  • We aimed to evaluate blood coagulation parameters and platelet indices as potential predictors for the onset and severity of PE. (
  • Furthermore, OCT has the potential to represent the process of flowing blood coagulation with proper parameters. (
  • Dr Christine Nadziejko of the New York University School of Medicine hypothesized that exposure of healthy rats to ambient particles may cause changes in blood coagulation parameters. (
  • The investigators objective is to prove the hypothesis that particulate matter may exert its adverse health effects by altering blood coagulation parameters. (
  • Dr. Nadziejko and her colleagues at the New York University School of Medicine plan to evaluate the effects of exposing healthy rats to concentrated ambient particles (CAPs) and changes in blood coagulation parameters. (
  • Investigators expect the results to show altered blood coagulation parameters in rats exposed to CAPs. (
  • The kinetic model consisting of 76 ordinary differential equations (76 species, 57 reactions, 105 kinetic parameters) predicted the clotting of resting and convulxin-activated human blood as well as predicted T i of human blood under 50 different initial conditions that titrated increasing levels of TF, Xa, Va, XIa, IXa, and VIIa. (
  • In such procedures blood parameters can drastically change within the lapse of a few seconds to minutes due to exposure of patients' haemostatic system to large disturbances such as haemo-dilution or anticoagulation. (
  • When the inflammation-coagulation interactions overwhelm the natural defence systems, catastrophic events occur, such as manifested in severe sepsis or inflammatory bowel disease. (
  • We used repeated measurements to examine the association of long-term fine and ultrafine particle exposure with several blood markers of inflammation and coagulation. (
  • E. W. Davie, K. Fujikawa, M. E. Legaz and H. Kato, "Role of Proteases in Blood Coagulation," in Proteases and Biological Control , ed. by E. Reich et al, Vol. 2 of Cold Spring Harbor Conference on Cell Proliferation, 1975. (
  • L1106] Hemophilia A is a hereditary hemorrhagic disorder generated by the congenital deficit of the coagulation factor VIII. (
  • Also searched for Hemostatic disorder and Coagulation disorder . (
  • Hemophilia A, a genetic bleeding disorder, is often caused by chromosomal inversions that involve a portion of the blood coagulation factor VIII ( F8 ) gene that encodes one of the key enzymes in blood clotting. (
  • Tabuchi and colleagues 7 observed increased fibrinolytic activity in blood aspirated from the pericardial cavity during clinical cardiac surgery and suggested that raising pericardial blood heparin concentrations may reduce blood activation during CPB. (
  • In PE patients, the coagulation-fibrinolytic system is thought to be one of the most seriously affected systems by maternal inflammatory reactions and immune dysfunction [5] . (
  • In light of this, the present study aims to systemically evaluate the blood coagulation and fibrinolytic systems in CAE patients. (
  • Disequilibrium of the coagulation/fibrinolytic system may contribute to thrombus formation and clinical coronary events in patients with CAE. (
  • Bennett NB, Ogston CM, Ogston D. The effect of prolonged exercise on the components of the blood fibrinolytic enzyme system. (
  • Different blood conservation strategies were used and included consistently cell salvage, standardized application of tranexamic acid and retrograde autologous cardiopulmonary bypass (CPB) priming. (
  • Experiments with combined anti-XI and anti-XII antibodies prevented thrombin production, demonstrating that a leak of XIIa past saturating amounts of CTI (and not "blood-borne TF" alone) was responsible for in vitro initiation without added TF. (
  • If a mammalian blood vessel is severed, it immediately contracts to limit the flow of blood. (
  • Coagulation is an important part of the haemostasis process corresponding to the cessation of blood loss from a damaged vessel. (
  • It is a fast acting system that has multiple steps to reduce blood loss, temporarily and then permanently plug the leak until the integrity of the blood vessel is restored. (
  • Blood coagulation does not just start immediately after the formation of a platelet plug but is rather the consequence of a series of steps that commences with vessel injury. (
  • It may also be triggered by trauma to the blood cells in an otherwise intact blood vessel. (
  • Coagulation begins almost instantly after an injury to the endothelium lining a blood vessel. (
  • For use in the emergency reversal of coagulation factor deficiency in patients receiving vitamin K antagonist therapy. (
  • Earlier this year, Roche launched the CoaguChek INRange system in Europe , which helps patients and doctors monitor coagulation and response to vitamin K antagonist therapy. (
  • The thread is of a material to which blood coagulation substances adhere, preferably a water wettable material such as glass, or plant or animal fibers, e.g., cotton or wool. (
  • The preventative effect of caffeic acid phenyl ester (CAPE) against hematological, blood coagulation, and hepatorenal disturbances in cadmium (Cd) intoxication was investigated in rats. (
  • It is concluded that CAPE is a promising compound that can counteract the hematological and blood coagulation disturbances, oxidative stress, and hepatorenal damages in Cd intoxication. (
  • Professor Francesco Violi at Sapienza University of Rome suspects that the disturbances in the blood clotting mechanism play a central role in the disease. (
  • Surface-energy dependent contact activation of blood factor XII. (
  • The simultaneous increase of TF concentration and activity, VEGF-A in the blood of patients with ET, as well as a positive correlation between the concentration of TF and VEGF-A demonstrates the coexistence of TF-dependent coagulation and activation of angiogenesis. (
  • Acute exercise causes a temporary short lasting activation of blood coagulation, platelet function and the prostaglandin system, the extent of these alterations being significantly less pronounced in well trained athletes than in untrained persons. (
  • Their utility as molecular wires has also led to their incorporation into redox reactions in higher‐order organisms, where they participate in numerous physiological processes, including blood coagulation. (
  • Pro-coagulation tube is used in blood collection for biochemistry and immunology in medical inspection. (
  • Coagulation, meanwhile, involves a complicated dance between cell membranes and biological molecules. (
  • Conclusions The authors observed different temperature effects on blood markers in two potentially susceptible groups probably indicating varying underlying biological mechanisms. (
  • Faced with a bleeding patient, it may be difficult to determine whether blood loss is due to a local factor, or an underlying hemostatic defect. (
  • Faced with a bleeding sufferer, it can be tough to figure out even if blood loss is because of an area issue or an underlying hemostatic illness. (
  • Almost the entire hemostatic mechanism is regulated by various chemicals that are in constant circulation in the blood stream. (
  • Objectives Changes in air temperature are associated with an increase in cardiovascular events, but the role of procoagulant and proinflammatory blood markers is still poorly understood. (
  • Over eight years, the known INRatio problems became linked to more than a dozen deaths and hundreds of injuries, including gastrointestinal bleeding, bleeding requiring surgery such as endoscopic cautery or repair, bleeding requiring a blood transfusion, intra-cerebral hemorrhaging, and cardiovascular events following a bleeding episode. (
  • Today marks the third lustrum of the annual international sympo- sium on blood transfusion, organized by the Rode Kruis Bloedbank Groningen-Drenthe. (
  • I am happy to note that the initiative has been successful: over the past fourteen years the Rode Kruis Bloedbank Groningen-Drenthe has succeeded in organizing an annual symposium on blood transfusion, with a different theme each year, and with an average attendance of 250 participants from some 26 countries world-wide. (
  • Implementing coagulation management algorithms based on Point-of-care (POC) testing devices such as thromboelastography (TEG) or rotational thromboelastometry (ROTEM) have been shown to reduce transfusion rates and the occurrence of adverse patient outcomes. (
  • Indication for red blood cells (RBC) transfusion were a hematocrit (HCT) level below 21% during CPB, below 25% for patients with preserved left ventricular function and 28% for patients with a left ventricular function ≤ 30% and patients undergoing emergency procedures. (
  • in all mammals, coagulation includes both a cellular (platelet) and a protein (coagulation factor) component. (
  • For example, one of the most widely used and accepted laboratory method involves periodically tipping or rotating end-forend a plurality of tubes containing blood samples every thirty seconds until the blood maintains its shape when the tubes are inverted. (
  • Which of the following involves excessive clotting of blood? (
  • We have developed and investigated a novel optical approach, Laser Speckle Rheology (LSR), to evaluate a patient's coagulation status by measuring the viscoelastic properties of blood during coagulation. (
  • The synthesis of a series of novel macrocyclic compounds designed to target blood coagulation Factor XIa is described. (
  • BACKGROUND OF THE INVENTION The present invention relates to the testing of blood coagulation or clotting time and, more particularly, to novel and improved methods and apparatus for invitro testing of coagulation of fresh samples of venous blood. (
  • A further major object is to provide blood coagulation test methods and apparatus which generally operate 3,814,585 Patented June 4, 1974 to provide a test endpoint in less time than conventional tests providing the same information. (
  • To consider the effect of blood flow, in the present study, d 1/e versus time from the coagulating porcine blood circulated in a mock flow loop with various steady laminar flows at mean flow speed in the range from 5 to 25 mm/s . (
  • The results showed that there were positive correlations between coagulation time (t c ) and HCT, velocity, and tubing size, respectively. (
  • Elasticity varied with time from 50 Pa at coagulation to 1300 Pa at 120 minutes. (
  • A system and method for determining a coagulation time, e.g. (
  • Resistance to agitator movement due to coagulation is detected, and the coagulation time is measured. (
  • Ongoing patent expirations and failed life cycle management efforts leave the established companies vulnerable regarding the future growth perspective of their recombinant coagulation factor business, but at the same time opens the door to potential new market entrants. (
  • We demonstrated that affinity based poly ethylene NPs absorbed to polymer films on the QCM constitute a powerful tool with no need for pretreatment for measuring PT in whole blood samples in real time, while these coatings are reusable up to 10 times. (
  • L1053] The hemophilia A is characterized by the deficiency of the coagulation factor VIII that results in prolonged blood flow after injury or surgery as well as recurrent bleeding. (
  • The coagulation factor VIII is a robust initiator of thrombin which is later required for the generation of fibrin to form a platelet plug and its gene is expressed in the X chromosome. (
  • We keep the following points in mind for the procedure of partial hepatectomy using a monopolar soft-coagulation device for hepatocellular carcinoma. (
  • Blood coagulation is viewed as a process resulting in fibrin polymerization, which is considered as the first step towards thrombi formation. (
  • Our previous work demonstrated that an optical coherence tomography (OCT) technique was able to characterize the whole blood coagulation process. (
  • The 1/ e light penetration depth ( d 1/ e ) derived from the profiles of reflectance versus depth was developed for detecting the whole blood coagulation process in static state. (
  • Xiangqun Xu , Xiangqun Xu, Jinhai Geng , Jinhai Geng, Xiangshuai Teng , Xiangshuai Teng, } "Monitoring the blood coagulation process under various flow conditions with optical coherence tomography," Journal of Biomedical Optics 19(4), 046021 (29 April 2014). (
  • We hope our proposed surface modification process is a step forward towards obtaining blood compatible catheters and hopefully it would be used in future studies and on other medical devices," added Badv. (
  • You will probably need regular blood tests to check how well your blood is clotting. (
  • Blood clotting. (
  • Roche unveiled a new app for patients on anticoagulation therapy, allowing them to see results from their at-home blood clotting tests on an iOS device. (
  • They do so with the help of lipid molecules that ordinarily lie buried within the membranes themselves, rising to the surface only when needed-a regulatory mechanism that prevents your blood from clotting in your veins as you read this. (
  • In the normal healthy state, the anticoagulants dominate but once there is injury to the blood vessels, the procoagulants are activated and promote blood clotting. (
  • Prof. Violi has examined nine studies published by Chinese doctors since the start of the epidemic for laboratory results relating to blood clotting. (
  • McMaster University scholars have developed a novel technique to minimize catheter-associated blood clotting. (
  • Tohid Didar, assistant professor, Department of Mechanical Engineering and the School of Biomedical Engineering and his team determined that a lubricant-infused catheter coating produced through chemical vapor disposition (CVD) reduces blood clotting. (
  • Blood function defines bleeding and clotting risks and dictates approaches for clinical intervention. (
  • How are blood coagulation and blood clotting different? (
  • Clotting and coagulation are used as synonims. (
  • Is it true that clotting of blood is same as coagulation of blood? (
  • I'm having symptoms of blood clotting. (
  • Bloods and a little clotting when my husband wiped? (
  • How is blood clotting bad? (
  • What causes blood clotting? (
  • How to control the blood clotting? (
  • What are the steps in your blood clotting? (
  • Egeberg O. The effects of exercise on blood clotting system. (
  • Activated blood coagulation factor XI may refer to: Coagulation factor IXa, an enzyme Coagulation factor XIa, an enzyme This disambiguation page lists articles associated with the title Activated blood coagulation factor XI. (
  • The following discussion will review tumor-derived procoagulants with emphasis on evidence for a unique tumor-derived proteolytic enzyme that initiates blood coagulation (for further evidence see Chapter 12). (